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Abstract 
Radiation skin reactions are a common side effect of radiation therapy and can be distressing and 
painful for patients. Head and neck cancer patients receive a high dose of radiation to the skin and are 
therefore at high risk of acute skin toxicity. There have been many clinical trials investigating topical 
agents to reduce or prevent these reactions but the evidence to date is lacking and many centres still 
base their practice on anecdotal evidence. Recently clinical trials in breast cancer patients have shown 
that using Mepitel Film® (Mölnlycke Health Care AB, Gothenburg, Sweden) reduced skin reaction 
severity and stopped the development of moist desquamation when used prophylactically (from the 
first day of radiation therapy). Mepitel Film and other soft silicone dressings that adhere very closely 
to the folds of the skin, have been hypothesized to decrease skin reaction severity by stopping friction 
by clothing and allow the radiation damaged skin to repair itself. 
 
The aim of this randomised controlled feasibility study in this thesis was to investigate whether 
Mepitel Film dressings were superior to Sorbolene cream in reducing or managing radiation-induced 
skin reactions in patients with head and neck cancer Head and neck cancer patients are prescribed a 
higher dose than breast cancer patients, have an uneven surface for the Mepitel Film to adhere to and 
have complex non-homogenous dose distributions, This means that testing the effect of Mepitel Film 
in this cohort would be challenging. Despite this, it was hypothesised that Mepitel Film was superior 
to standard Sorbolene cream in decreasing the severity of acute radiation-induced skin reaction in 
patients receiving radiation therapy for head and neck cancer. 
 
In order to test this hypothesis a randomised, controlled, multi-centre, international, open label intra-
patient feasibility study was conducted in New Zealand and China. This thesis analyses a subset of 12 
patients recruited at the Canterbury Regional Cancer and Haematology Service (CRCHS) at 
Christchurch Public Hospital. For the first six patients, the study area was chosen as the area of first 
erythema which was divided into equal halves. Each half was randomised to either Mepitel Film or 
Sorbolene cream. Mepitel Film was applied as soon as erythema was visible (management protocol). 
For the next six patients, the study area was chosen at the planning stage to include an area of 
relatively uniform high dose (>40Gy). This area was divided into two equal halves; one half was 
randomised to Mepitel Film the other half to Sorbolene cream. Mepitel Film was applied from day one 
of radiation therapy treatment (prophylactic protocol). Sorbolene cream was applied twice a day by 
the patient. The Modified Radiation-induced Skin Reaction Assessment Scale (RISRAS) and the 
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reaction severity three times a week. Patients also filled out the New Zealand validated Distress 
screening tool once a week and completed exit questionnaires at the end of the follow-up period. 
Thermoluminescent dosimeters (TLDs) were used to measure the actual dose to the skin underneath 
Mepitel Film and the control cream for all patients. 
 
When results of all 12 patients were combined, there was a statistically significant decrease in skin 
reaction severity in favour of Mepitel Film of 29% for combined scores, of 15% for researcher scores 
and of 49% for patients’ scores (p= 0.001, 0.002 and 0.004 respectively). The difference in peak RISRAS 
score between skin covered with Mepitel Film and control skin covered in cream was also significantly 
lower (p=0.02). The results were disappointing compared to those reported by the breast cancer trial 
where skin reaction severity was reduced by more than 90% when Mepitel Film was used 
prophylactically. Several factors may explain the lack of effectiveness of the Mepitel Film in this patient 
cohort. Dose to the skin was significantly higher in head and neck cancer patients and Mepitel Film 
did not adhere well to skin with heavy beard stubble, which meant Mepitel Film needed to be replaced 
almost daily for the first few weeks of radiation therapy. The latter may also explain why there was no 
difference in the Mepitel Film effect between the skin of patients on the management protocol and 
those on the prophylactic protocol which should have had the strongest skin protective effect. In 
addition, compared with skin covering the breast area, skin in the neck area may be “tougher” and 
less likely to benefit from “friction protection”. 
 
The results suggest that Mepitel Film does reduce skin reaction severity in head and neck cancer 
patients but the increase in skin folds, beard growth and high skin dose mean that the protective 
effects of Mepitel Film are limited, particularly in men with heavy beard growth. Mepitel Film 
appeared to be more effective in women but there were too few women in this trial to perform a 
statistically meaningful analysis. Future research should include clinical studies in different cohorts of 
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Chapter 1 Introduction 
Cancer of the head and neck applies to mucosal cancers of the oral cavity and lip, pharynx, larynx and 
cervical oesophagus (1). It also includes the nasal cavity, paranasal sinuses and salivary glands (1). 
Rapid increases in the incidence of oral pharyngeal cancers have been found in both Australia and 
New Zealand, attributed largely to increased rates of Human Papilloma Virus in the population (2). 
Standard treatment for early or locally advanced cancers commonly include radiation therapy, as well 
as chemotherapy for those with high risk features (3). 
 
Radiation-induced skin reactions occur commonly in everyday practice and are therefore important 
to consider when caring for oncology patients (4).  Radiation reactions are a complex injury and can 
occur at the entry or exit  point of the radiation beam (5). Radiation-induced skin reactions can occur 
in up to 90% of breast and head and neck cancer patients and although the incidence of moist 
desquamation overall can be low, it can be distressing and painful for the patients (6). Skin toxicity 
during treatment while distressing for the patient can also result in treatment delays in severe cases 
which can negatively impact the overall treatment (7). 
 
Recent systematic reviews of the literature have shown a lack of strong evidence, in the form of 
randomised controlled clinical trials (RCTs), to support the use of any topical agent in reducing the 
incidence or severity of radiation-induced skin reactions (7,8). Due to this lack of evidence there is 
considerable variation in practice across Australasia, with 50% of centres reporting their skin care 
policy was based on anecdotal evidence (9). 
 
A recent RCT conducted in New Zealand demonstrated the efficacy of Mepitel Film in significantly 
decreasing skin reaction severity for breast cancer patients by 90%, by reducing friction and trauma 
to the irradiated skin (10). Head and neck cancer patients pose a particular challenge for the use of 
dressings, due to the change in contour over the neck, facial hair and the higher dose of radiation 
prescribed to this patient group compared to breast cancer patients.  
 
In order to test the effectiveness of Mepitel Film on head and neck cancer patients, a multi-centre, 
international, open-label, randomised, intra-individual comparison of Mepitel Film dressings versus 
Sorbolene Cream during radiation therapy in New Zealand is being conducted. This thesis reports the 
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1.1 The structure of the skin and its response to radiation 
The skin is a multi-layered structure composed of the epidermis and dermis (11–13).  The dermis 
consists of a papillary layer and a reticular layer (see Figure 1.1). The papillary layer contains nerves, 
hair follicles glandular tissue and blood vessels (6,11). The stem cells in the basal layer of the epidermis 
replace cells by dividing with daughter cells travelling to the surface, which takes approximately 2 
weeks (11,13). The basal layer is continually dividing and thus is particularly sensitive to damage by 
ionizing radiation (6). Radiation therapy causes ionizing events and the production of free radicals 
which damage cellular DNA and can cause cell death (14). Stem cell division is impaired and thus 
normal tissue turnover is reduced. The continued assault on the basal layer from fractionated 
radiation therapy causes the stem cells to produce cytokines which recruit circulating immune cells, 
contributing to an inflammatory environment (15). This leads to chronic free radical production 
reducing the stem cell population further, resulting in radiation-induced skin reactions (15). 
 
 
Acute skin reactions develop within 2 to 3 weeks of irradiation and exhibit varying degrees of severity, 
including erythema and dry and/or moist desquamation followed by a process of healing (16). 




Erythema is defined as reddening of the skin and is caused by the dilation of capillary vessels within 
the dermis and oedema (17–19). The inflammatory reactions that cause erythema are mediated by 
cytokines. A histamine-like substance is released, leaving the skin red and itchy (18).  Erythema can 
manifest by varying shades of red depending on the dose delivered to that area (18,19).  Standard 
fractionation regimen (2Gy per fraction, 5 days a week) can show light erythema  at total doses of 20-
25Gy (17,19,20).  
 
Dry Desquamation 
As the dose of radiation is increased, dry desquamation can develop. This is characterised by dry flaky 
skin (6,19). This occurs when new cells divide and migrate to the skin surface faster than the old ones 
are shed (18). This occurs approximately 4 weeks after the start of irradiation, following a 2Gy per 
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Moist desquamation 
Moist desquamation is manifested by blistering, peeling and sloughing of the skin’s surface and often 
pain (6,21). It is caused by the complete destruction of stem cells in the basal layer and thus skin 
cannot be replaced at the surface (6,13). This usually occurs after 4 or 5 weeks of radiation, with doses 
of 40Gy or more, following a 2Gy per fraction regimen (21,22). Moist desquamation is the most 
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1.2  Factors effecting the severity of skin reactions 
The severity of radiation skin reactions is dependent on a number of intrinsic and extrinsic factors of 
which dose is a core influence (6,13,16,17,23).  The intrinsic or patient-related factors include age, skin 
type, smoking, nutritional status, performance status, co-morbidities. The extrinsic factors include 
radiation dose, use of build-up material, and fractionation (16). Porock describes the factors affecting 
skin reactions as a conceptual framework and allocates each factor into a treatment, genetic or patient 
construct (16,23). These factors are listed in Table 1.1. 
 
Table 1.1 - Factors affecting skin reaction severity (adapted from (16,23)).  
Treatment Patient Lifestyle 
Radiation dose gender obesity  
Radiation volume ethnicity  smoking  
Radiation fractionation age nutritional status  
Tumour site  comorbidities  
Radiation technique   
Concurrent chemotherapy   
 
 
1.2.1 Treatment-related factors 
Dose, site and fractionation 
There is a close relationship between dose and fractionation regimen in the development of skin 
reactions, as these are based on tissue tolerances (16). Porock and colleagues reported a  definitive 
dose-response relationship between severity of skin reaction and the dose received (23). At about 
50Gy repopulation no longer mitigates the cells lost by radiation damage (17). Head and neck cancer 
patients often receive doses in excess of 60Gy to the tumour (24,25). Severe radiation dermatitis 
therefore cannot be avoided in these patients as the target volume is very close to the skin (7). Patients 
with tumours located close to the skin, as can be seen in breast and head and neck cancer patients, 
will receive a much higher dose to the skin than patients with deeper tumours in other body locations. 
 
Radiation type  
The effect of radiation on the skin is also dependent on the type of radiation used. Radiation particles 
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produced by linear accelerators, delivers maximum dose deep into the tissues, sparing superficial 
structures such as the skin from the highest doses(6,17).  
 
Treatment planning techniques 
Recent advances in treatment planning have decreased skin dose and thus skin reaction severity. 
Intensity Modulated Radiation Therapy (IMRT) is an inverse planning technique that uses a 
sophisticated planning algorithm and non-uniform beam intensities to more accurately shape the dose 
of radiation to the target and help spare normal tissue compared to conventional 3 dimensional 
conformal radiotherapy (3DCRT) (26,27). The use of more complex planning techniques such as IMRT 
and Volumetric Arc Therapy (VMAT) have led to a reduction in moist desquamation for head and neck 
cancer patients (24,27).  However grade 3 or higher dermatitis is still present in approximately 10% of 
patients and brisk erythema still occurs in the majority of patients (24,27). Areas of skin can be 
deliberately targeted to reduce the dose in that area, however some superficial areas within the target 
volume can still be at high risk (28).  
 
Immobilisation and build-up (bolus) material 
Radiation therapy for head and neck cancer patients requires precise setup procedures due to the 
close proximity of organs at risk, such as the parotid glands and spinal cord to the tumour (29). 
Immobilisation devices are therefore important to reduce setup variation to ensure that the treatment 
is delivered to exactly the same volume every fraction (29). Interestingly, this dose build-up effect is 
also seen in skin folds, with the most severe radiation reactions in patients receiving high doses in 
areas of skin folds (23). Skin folds can trap moisture and thus lead to worse skin reactions and infection 
(28). 
 
Radiation reactions are exacerbated by multiple tangential-to-skin beams and the use of 
immobilisation devices (7). Lee et al. conducted dosimetric studies evaluating the skin dose using 
extended field IMRT. The measurements on their phantom showed an increased dose to the skin when 
a thermoplastic mask was used, showing it had a build-up or bolus effect (30). Bolus is a tissue-
equivalent material, acting as tissue, to allow the beam to deposit a higher energy closer to the 
surface. This causes the skin to absorb the higher dose that underlying tissue would have received 
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Chemotherapy 
Chemotherapy agents are used to destroy cancer cells on their own or improve the effects of radiation 
therapy by acting as a radiosensitiser (16,23). In head and neck cancer patients, Cetuximab increases 
the rate of severe skin reactions 10 fold compared to radiation alone, with the incidence of moist 
desquamation as high as 49% (31–33). Other chemotherapy agents that are likely to have an additive 
damaging effect to radiation on the skin are 5-Fluorouracil, Adriamycin (Doxorubicin), and 
Methotrexate (16). DNA has been identified as the critical target for platin-based agents such as 
Cisplatin, as well as inducing reactive oxygen species that can trigger cell death by different pathways 
(34). Palazzi et al. reported that adding chemotherapy to radiation for head and neck cancer patients 




1.2.2. Patient-related factors 
 
Gender 
Several gender-linked differences have been described for human skin. The stratum corneum and 
epidermis are thicker in men than in women (36). Men are more prone to skin cancer and bacterial 
and viral infections, whereas women are more prone to autoimmune and inflammatory diseases (37). 
This may explain the greater acute and long term radiation toxicities found in female head and neck 
patients in a study by Meyer et al. (38). The authors found Odds Ratios for developing acute (1.72) and 
late (3.96) toxicities for females (n= 110) compared to males (n=417). In a different study by Dehing-
Oberrije and colleagues, female lung cancer patients (n= 142) were also shown to have a higher rate 
of radiation-induced dysphagia (OR 1.65, p=0.011) than male patients (n=327)  (39).  
 
Ethnicity 
It has been hypothesised that people with darker skin would experience less severe radiation-induced 
skin reactions than people with a fair skin (16). The increased number of melanocytes which protect 
the underlying stem cells from damage from Ultra Violet (UV) radiation is thought to also protect the 
cells from ionising radiation. One study found that patients with fairer skin had worse skin reactions 
but reacted better to a steroid cream than patients with a darker skin (40). This however was not 
supported by Ryan and colleagues who found that patients with darker skin actually reported worse 
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show a correlation between skin type and radiation skin reactions (10,42). In fact some authors 
suggest that people with dark skin may in fact have worse skin reactions. Melanin does not protect 
the nucleus from ionising radiation but causes an increase in free radical production during melanin 
production, resulting in more rather than less DNA damage and worse skin reactions (15).  
 
Age 
As a person ages, the epidermal turnover decreases resulting in thinner skin with a decreased healing 
capacity (23,43). Every stage of the healing process has shown age related changes in clinical studies 
(43). However, the effect of age on radiation-induced skin reactions is less clear. Turesson et al. failed 
to prove that age was significantly associated with acute skin reaction severity in a multivariate 
analysis for 402 breast cancer patients (44). Severe acute and late toxicities in clinical trial of 540 head 
and neck cancer patients were also not associated with age (38). In fact, younger age was shown by 
Palazzi et al. (35) to be a statistically significant predictor of radiation dermatitis (p=0.03), in a study 
of 149 head and neck cancer patients. 
 
 
1.2.3 Lifestyle-related factors 
 
Obesity 
Adipose tissue effects healing due to its hypo-vascularity and its release of specific adipokines that 
may inhibit the immune response (16,43). Obesity can also cause excessive wear on the skin through 
increased friction caused by skin on skin contact and larger skin folds (16,43). These skin folds can also 
harbour potentially harmful microorganisms which can cause wound complications (43). Meyer et al. 
reported in their study of 540 head and neck cancer patients that patients with a Body Mass Index 
(BMI) of greater than 25 were 1.88 times more likely to have severe acute or late radiation-induced 
toxicities than patients within the healthy weight range (38). Sharp et al. also found high BMI to be a 
significant factor predicting severe radiation skin reactions in a randomised study testing two different 
skin care formulations in 390 patients with breast cancer (45). 
 
Smoking 
Smoking has been shown to not only increase the risk of several chronic diseases but also has a 
detrimental effect on wound healing (43). The supply of oxygen to tissues is compromised by 
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in the blood, causing hypoxia (43). Sharp et al. reported that in addition to obesity, smoking was also 
significantly associated with severe radiation skin reactions on multivariate analysis (45). 
 
Nutritional Status 
Nutrition plays a key role in wound repair. Glucose, in the form of carbohydrates, is the main energy 
source for cellular renewal and the formation of blood vessels (43). Protein deficiency decreases all 
metabolic activities, including the production and activity of immune cells thus increasing the 
susceptibility to infection. Proteins are responsible for a number of important processes including 
collagen synthesis and wound remodelling (43). Vitamins and several micronutrients have also been 
shown to be essential in the wound healing process especially Vitamin A, C, E, magnesium, copper zinc 
and iron (43). 
 
Comorbidities 
There are a number of inherited syndromes that cause hypersensitive skin reactions in response to 
radiation. These include ataxia telangiectasia, Bloom’s syndrome, Fanconi’s anaemia, retinoblastoma, 
Down’s syndrome and basal cell nevus syndrome (16,23). The genetic susceptibility of these diseases 
to radiation damage is thought to be linked to chromosomal fragility or failed DNA strand break 
recognition and mis-repair (46). Diabetes is a well-known factor influencing cellular repair. This is 
thought to be due to impaired vascularity which results in lack of nutritional support and poorly 
oxygenated tissues (43). Both oxygen and nutrients are essential in cellular repair and metabolism and 
promote healing.  
 
Other factors that affect skin reaction severity in addition to those covered by Porock(16,23): 
 
Stress 
Recent evidence suggests that patient stress can negatively affect wound healing. Any form of stress 
increases the production of glucocorticosteriods such as cortisol by the adrenal cortex. This produces 
a more inflammatory environment, fuelling the inflammatory skin reaction process  (43,47). With 
respect to wound healing, high cortisol levels impair all three phases of wound healing, inflammation, 
proliferation and remodelling (48). Anxiety and depression as well as physical stress have been 
associated with delayed healing of chronic wounds in several clinical studies.  
 
Ebrecht et al. (49) investigated stress and wound healing by assessing punch biopsy healing in 24 
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Stress Scores and elevated cortisol levels in the morning. Another study investigated the effect of 
laughter therapy on skin reaction severity in 37 breast cancer patients (50). This was not a randomised 
study but showed that the laughter therapy intervention group developed less severe skin reactions. 
In the laughter therapy group, grade 3 and 2 reactions were seen in 33% and 33% of patients 
respectively, whereas in the control group grade 3 and 2 reactions were seen in 36.8% and 47.4% of 
patients (p=0.053). Although there has not been any research on stress and radiation-induced skin 
reactions, the fact that stress exacerbates inflammatory skin conditions such as atopic dermatitis and 
psoriasis (48) makes it plausible that stress may also aggravate radiation dermatitis. 
 
 
Human Papilloma Virus (HPV) 
HPV infection has been associated with the development of head and neck cancer (51). P16 
overexpression has been accepted as a biomarker for HPV oncoproteins (52). Becker-Schiebe et al. 
retrospectively assessed 79 head and neck cancer patients and found that p16 positivity was 
significantly associated with acute grade 3 skin toxicity. The authors stated that this finding may be 
explained by HPV infected mucosal tissue possibly enhancing radiation related inflammation by 
affecting the basal layer of the skin (52). Patients with HPV positive cancers have a better prognosis, 
which has been attributed to better local control due to the greater radiosensitivity of HPV positive 
tumours compared with HPV negative tumours (53). 
 
Haemoglobin levels 
Up to 30% of cancer patients can present with anaemia largely caused by a blunted erythropoietin 
response, disordered iron metabolism, increased levels of inflammatory cytokines and tumour burden 
metabolic changes (54). Hypoxia has been shown to increase the genetic instability of cancer cells, 
which can result in daughter cells with diminished apoptotic potential and/or increased therapy 
resistance (55). Oxygen is known to increase the effectiveness of radiation therapy two-three fold. 
Oxygen forms oxygen-derived free radicals which increase radiation-induced DNA damage (56). The 
damage caused by other free radicals to the DNA backbone can be fixed under hypoxic conditions but 
made permanent by interactions with oxygen (56). The impact of  haemoglobin levels on acute normal 
tissue toxicity during chemoradiation for cervical cancer was evidenced by high haemoglobin levels 
(›12gm/dl) significantly worsening acute mucotaneous toxicity (57). A similar study for head and neck 
patients (n=79) also found that the risk of severe skin toxicities was reduced for patients with hypoxic 
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Friction of radiation damaged skin 
The most recent addition to the “factors that affect skin reaction severity” has been described by Herst 
(15). In addition to being damaged on a daily basis by ionising radiation, skin is also subject to friction 
stresses caused by clothing and other body parts. This is particularly important for tumours close to 
the skin that already receive a much higher dose than deeper tumours. Breast and head and neck 
cancer patients are most likely to suffer from radiation-induced skin reactions due to the combination 
of high skin dose and high friction levels. This new angle of skin reaction severity has opened the road 
to new treatment approaches, which will be discussed in more detail later in this thesis and which 
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1.3 Prevention of radiation-induced skin reactions 
Radiation-induced skin reactions are a common occurrence for breast cancer and head and neck 
cancer patients (16). However, the latest skin  review by Chan et al. in 2014 (8) found no evidence to 
support the use of any topical agents for preventing radiation-induced skin reactions. Their review 
included 47 studies and analysed the effect of various interventions on development and symptom 
severity of skin reactions as well as several secondary objectives including quality of life. Oral 
therapies, skin care practices, topical ointments and some dressings were all included in the analysis. 
The authors commented on the small size of most studies and the lack of good quality randomised 
controlled trials. They did not discourage the use of soap for washing and deodorant. Practice across 
Australia and New Zealand is also inconsistent and a recent survey showed that 50% of respondent 
departments based their skin care advice on anecdotal evidence (9). Similar finding have been 
reported in Europe and the USA (58). 
 
The following section provides an overview of the literature investigating topical agents for the 
prevention of radiation-induced skin reactions published since the review by Chan et al. It is not 
intended as a comprehensive systematic review and only includes English language articles available 
from the University of Otago.  A total of nine studies were identified and are summarised in detail in 
Appendix A.  
 
Two studies assessed the use of transparent dressings on skin reaction severity. Ariumra et al. (59) 
compared Airwall tape to conventional treatment of Dimethyl isopropylazulene for grade 1 reactions, 
Betamethasone valerate for grade 2 and Betamethasone valerate or Gentamicin sulfate for grade 3 
reactions in 271 prostate cancer patients. Airwall tape was described as a colourless transparent tape, 
7µm thick. The results did show a statistically significant difference between the development of grade 
2 and 3 reactions between the intervention and control groups (21 and 0 vs 57 and 4, p <0.001). A 
total of 18 patients in the intervention group however stopped applying the film citing itching 
sensation, skin redness and folliculitis.  This study was limited by the fact that it was not randomised 
and patients chose which group they wanted to participate in, creating unavoidable selection bias. 
The skin was assessed every two days until the patients finished and then the patients sent in photos 
of the skin for analysis once a week for a month. There was no mention of ensuring the photos were 
of sufficient quality for analysis. There authors said in correspondence dated 18th January 2016 that 
doses were compared using Dose Volume Histograms in the planning system but no independent skin 
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Herst et al. (10) compared the effect on skin reactions of a silicone-based film to aqueous control 
cream in a randomised intra-patient controlled RCT of 78 breast cancer patients. Participants had their 
breast/chest wall divided into two equal halves (medial and lateral) which were randomly assigned to 
either aqueous cream or Mepitel Film. Mepitel Film was applied prophylactically from the first day of 
radiation therapy. The assessors used the RTOG scale (60) and modified Radiation-induced Skin 
Assessment Scale (RISRAS) (19,61) to assess skin reaction severity three times a week during 
treatment and once a week for 4 weeks after completion of treatment. The results showed the skin 
underneath the Mepitel Film did not develop moist desquamation compared to 26% of aqueous cream 
treated skin. Overall, skin reaction severity was reduced by 92% (p<0.0001). This randomised study 
was much more robust than that of Arimura et al. as Herst et al. used patients as their own controls 
and TLDs to measure the dose to each skin area.  
 
Recent evidence suggests that aqueous cream damages the skin barrier most likely due to the sodium 
lauryl sulphate (SLS) in its formulation (62,63). It is therefore no longer recommended as a leave-on 
emollient. Herst et al. also showed a higher rate of moist desquamation in the conventionally 
fractionated group (50Gy in 25 fractions) compared to the hypofractionated group (40Gy in 15 
fractions) (10). This is important as hypofractionation is becoming increasingly common in this cohort 
of patients and is already the standard of care in the UK (64). 
 
Three trials assessed the use of oils in preventing skin reactions. Rollman et al. (65) randomly 
compared emu oil to cotton seed oil in 45 breast and chest wall patients. They used a variety of skin 
toxicity assessment tools but did not find a statistically significant difference between both arms. 
Cottonseed oil was used as a control as it has the same appearance as emu oil and thus this was a 
double-blinded study. Cottonseed oil however is not considered standard of care in countries across 
Europe or the USA (58) and thus is difficult to compare the results of this study to other international 
studies. This study would have benefited from the measuring the actual skin dose in the intervention 
and control areas, as well as larger patient numbers. 
 
On the other hand Cui et al. (66) compared olive oil to water in the prevention of radiation-induced 
skin reactions in 94 nasopharynx patients. They used the RTOG scoring and the Visual Analogue Scale 
(VAS) to assess skin reaction severity. The incidence of more severe reactions was less in the 
intervention group (6.4% vs 27.7% p<0.01) as were the average VAS scores. The results were 
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benefitted from independent assessment of the dose to the skin similar to the study above. It also did 
not mention what type of planning technique was used for these patients as IMRT can significantly 
reduce skin toxicity (24,27). Water was probably not the most appropriate control to use, as many 
centres recommend the use of a simple emollient cream (9). 
 
Palatty et al. (22)  compared a turmeric and sandalwood oil containing cream versus baby oil in 50 
head and neck cancer patients. There was a significant difference in the incidence and severity of 
grade III skin reactions in the cream group compared to baby oil.  Similar to most studies, this study 
also lacked an independent dose verification to the skin. The investigator was blinded but the patients 
were not. The investigator chose the area of worst skin reaction in the whole treatment area which 
would have varied between patients introducing selection bias. The criteria for choosing which area 
had the worst skin reaction were not reported. 
 
Three studies evaluated the use of creams in preventing radiation-induced skin reactions. Chan et al. 
(67) compared Allantoin to aqueous cream in 174 breast, lung and head and neck patients. Although 
Allantoin was supported by anecdotal evidence, it did no better than aqueous cream in preventing 
skin reactions. The trial was strengthened by its double-blinded design, however similar to other 
studies there was no independent measure of skin dose and the inclusion of several different types of 
cancer made the results harder to compare. The use of aqueous cream has been largely discredited 
and should not be used as a leave on emollient(62,63,68). 
 
Hindley et al. (69) compared the glucocorticosteroid Mometasone furoate (MF) to Disporboase (D) 
cream, which is an emollient similar to aqueous cream but does not contain SLS. A total of 120 breast 
cancer patients participated in the trial. The trial used the modified RTOG (60) scoring as well as 
diastron reflectance spectrometer to measure erythema and Hospital Anxiety and Depression (HAD) 
Scale(70) and the Dermatology Life Quality Index (DLQI)(71) questionnaires. The results showed a 
statistically significant difference in mean RTOG scores favouring the glucocorticosteroid, (mean 
difference 0.123 p=0.46). Patients in the MF group showed DLQI scores that were significantly less 
than the D group, but only for week 4 and 5. This study is unique in that it used a reflectance 
spectrometer in order to reduce observer bias when assessing degree of erythema in the skin, and its 
use of quality of life scores for the patients. 
 
The studies by Chan et al. and Hindley et al. have however been criticised, as the difference in RTOG 
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significant despite being statistically significant (72). However, this may just reflect the insensitivity of 
the RTOG scale. Using a more sensitive scale such as the RISRAS (19,61) may have produced a more 
pronounced difference. The trial by Chan et al. was praised for at least testing a natural based product 
to try to back up anecdotal evidence (72). 
 
Togni et al. (73) compared a Boswellia-based cream known for its strong anti-inflammatory properties 
to a ‘base cream’ on 114 breast cancer patients. Assessments used were RTOG scale and digital 
evaluation of colour magenta saturation using adobe photoshop. In patients using Boswellia cream 
the mean value of skin damage using photoshop was lower than that of the base cream group (10.1% 
vs 13.3%), p=0.009) however the difference in RTOG scores did not reach significance. This trial was 
not blinded and some patients reported disliking the smell of the Boswellia cream, and a non-absorbed 
residue was noted on patients’ skin. The trial also mentioned trends in itching and burning sensation 
however the assessment used to measure this was not mentioned. The assessments were done up to 
the last day of treatment and no follow-up was done after this. This is important as the peak skin 
reaction has been reported to occur two weeks after the completion of radiation therapy (42,74), so 
the peak skin reaction would not have been recorded. 
 
Finally, Manas et al. compared a water based gel plus Lactokine fluid (R1+R2) to a Urea cream (75). 
The study included 98 head and neck and breast cancer patients. The patients were assessed at four 
clinic visits, the week before treatment, 3-4 weeks from the start of treatment, at the end of treatment 
and then two weeks after treatment finished. CTC toxicity criteria were used as well as European 
Organisation for Research and Treatment of Cancer (EORTC) quality of life questionnaires. Fewer 
patients had skin reactions in the intervention group at all follow up appointments, and the results 
were statistically significant. At the fourth follow-up visit, 33% of patients presented with an acute 
skin reaction in the intervention group compared to 66% of patients in the control group (p=0.003). 
The authors however failed to give any information on patient demographics. It was difficult to know 
how good patient compliance was as they were only seen four times during the trial period. There was 
also no dosimetric evaluation of skin dose and the use of two very different cancer sites made the 
results difficult to interpret, as no sub-group analysis was described. The authors also said that quality 
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1.4 Management of Acute radiation-induced skin reactions 
 
The 2014 review by Chan et al. also did not find any significant studies of sufficient quality that showed 
any product was superior in managing radiation skin reactions once they had occurred. A literature 
review by Russi et al. in 2015 with a panel consisting of 32 multidisciplinary experts sought to establish 
consensus guidelines for the management of acute skin toxicity for head and neck cancer patients (7). 
One of the main limiting factors mentioned in this study was that many studies are small or 
retrospective and there are not many that specifically include head and neck cancer patients. They 
concluded that there was insufficient evidence to support using any particular dressing or advanced 
medication for the management of skin reactions, and that protecting the skin for further trauma was 
important. This section provides an overview of the literature investigating topical agents for the 
management of radiation-induced skin reactions published since the Russi et al. review, and includes 
trials using dressings that protect the skin from trauma, including Mepilex Lite (42). Mepitel Film was 
mentioned by the authors but the irregularity of the skin surface in head and neck cancer patients was 
mentioned as a difficulty in applying the Mepitel Film in this area. (7). Management is considered any 
strategy aimed at controlling established reactions in the form of erythema or dry/moist 
desquamation (8). It is not intended as a comprehensive systematic review and only includes English 
language articles available from the University of Otago. Studies that were single arm or pilot studies 
were excluded. A total of three studies were identified and summarised in Appendix B.  
 
Mepilex Lite dressings were examined by the same group that assessed Mepitel Film for the 
prevention of radiation-induced skin reactions. Paterson et al. (42) compared Mepilex Lite to aqueous 
cream in 80 chest wall patients once erythema had occurred. Both products have a soft silicon contact 
layer which adheres to healthy skin but does not stick to open wounds and minimises trauma on the 
skin from dressing changes. Bonded to the silicone webbing is a foam layer (Meplex Lite) or a 
breathable film (Mepitel Film). This trial was robust in its intra-patient controlled randomised design, 
the use of the RISRAS measure which is sensitive and has a patient component. Although there were 
no statistically significant difference in the incidence of moist desquamation between dressing and 
cream, the dressing reduced the overall severity of the skin reactions by 40%, which was statistically 
significant (p<0.001). In this multicentre trial dose to the skin was measured in two departments and 
inferred from treatment plans in two other departments. The authors mentioned that the dressings 
did not stick well on all areas and that because of the lack of transparency and bolus effect, they 
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Zhong et al. (76) assessed Mepilex Lite in 88 nasopharynx patients for management after moist 
desquamation. Similar to Patterson et al. they used RISRAS as well as the VAS pain and a Likert scale 
for neck mobility, sleep and appearance disturbance. The study showed there was a significant 
difference in time to wound healing with Mepilex Lite compared to the control in favour of Mepilex 
Lite (Median 16 days compared to 23 days, p=0.009). This study was difficult to assess however as the 
authors described time to wound healing as the complete re-epithelisation of all wounds, but then 
said the endpoint was dry desquamation. The planning techniques of patients varied considerably 
with 2D, 3D and IMRT utilised, and skin dose was not assessed. 
 
Bazire et al.(77) found that Hydrosorb dressings were no better than a simple water based spray in 
managing skin reactions in 278 breast cancer patients. Colourimetric evaluation was used with a 
chromameter for erythema. VAS was used to assess pain and DLQI was used to measure quality of life.  
Patients put the hydrosorb on themselves at home, with no mention of reproducibility of placement. 
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1.5 Aim and Objectives 
 
Aim 
The overall aim of this randomised controlled feasibility study was to investigate whether Mepitel Film 
dressings were superior to Sorbolene cream in reducing or managing radiation-induced skin reactions 
in patients with head and neck cancer.. In order to avoid skin thinning by aqueous cream, Sorbolene 
cream was used as a control cream. The effect of Mepitel Film was to be tested in a prophylactic 




1. Mepitel Film is superior to Sorbolene cream in decreasing the severity of acute radiation-
induced skin reaction in patients receiving radiation therapy for head and neck cancer 
2.  The prophylactic protocol is superior to the management protocol in protecting the skin from 
friction and reduce skin reaction severity 
 
In order to test these hypotheses this research consists of a randomised, controlled, multi-centre, 
international, open label intra-patient feasibility study. Patients are being recruited from public 
hospitals in Dunedin and Christchurch in NZ and Drum Tower Hospital in Nanjing in China. This thesis 
analyses a subset of 12 patients (six on the management protocol and six on the prophylactic protocol) 
recruited at the Canterbury Regional Cancer and Haematology Service (CRCHS) at Christchurch Public 
Hospital.   
 
Objectives 
1. To determine whether or not Mepitel Film is superior to standard Sorbolene cream in reducing  
skin reaction severity when used in a management setting. 
2. To determine whether or not Mepitel Film is superior to standard Sorbolene cream in reducing  
skin reaction severity when used in a prophylactic setting. 
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Measures 
1. Skin reaction severity was measured three times a week during radiation treatments and once 
a week for 4 weeks after completion of treatment using modified RISRAS(19,61) and modified 
RTOG(78).  
2. Stress levels were measured using the New Zealand validated Distress screening tool(79) once 
a week.  
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Chapter 2 Methods 
 
2.1 Research Design 
The overall feasibility study is a multi-centre international randomised intra-patient controlled pilot 
study comparing the efficacy of Mepitel Film versus Sorbolene cream in decreasing acute skin 
reactions during radiation to the head and neck. This thesis analyses the results of the first 12 patients 
of this trial, recruited at CRCHS. The first six patients were on a management protocol, where the 
interventions were applied from the moment faint erythema was visible. The last six patients were on 
the prophylactic protocol where the interventions were used from day one of radiation therapy. The 
trial is continuing to recruit patients in NZ and China at the time of writing. 
In order to make the results of this trial comparable to the results of previous trials involving Mepitel 
Film (10) and Mepilex Lite (42), a similar methodology was adopted. This included the use of similar 
skin reaction severity scoring instruments, the number of times skin reaction severity was determined 
and the intra-patient design, described in more detail below. 
 
The trial was approved by the University of Otago Ethics Committee for Health Research in September 
2014 (Reference number H14/111). Locality ethics approval was also obtained with the CDHB research 
office on 23rd December 2014. The trial is registered with the Australia and New Zealand Clinical Trials 
Registry (ACTRN12614000932662). The protocol was changed from a management to a prophylactic 
protocol in order to assess the effect of Mepitel Film on skin reactions when applied on the first day 
of treatment instead of at presentation of erythema. The amendment was approved by the Ethics 
committee on 17th September 2015.  The statistical significance between differences in Mepitel Film 
and control RISRAS scores was determined by paired two-tailed student T-test using Excel (Microsoft 
v 2010; Redmond Campus, Redmond, Washington, USA).    
 
2.2 Funding 
Salary for the Academic Principal Investigator/trial coordinator, Associate Professor Patries Herst was 
paid for by the University of Otago Wellington.  Salaries of the research radiation therapist, Bachelor 
of Radiation Therapy (Honours) student and author or the thesis, Hayley Wooding, and Clinical 
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Bachelor of Radiation Therapy (Honours) were funded by the Christchurch Hospital Oncology Trust 
fund.  
 
Mepitel Film was provided free of charge by Mölnycke Healthcare AB. Travel vouchers for patients 
($100 each) and Sorbolene cream ($25 each) were paid for by a research grant of the University of 
Otago. Travel vouchers were given to all patients participating in the trial to account for the increased 
number of follow-up appointments they were asked to attend as part of the trial compared to non-






 Age over 18 
 Receiving radiation therapy for mucosal squamous cell carcinoma (SCC) for head and neck 
cancer 
 Able to attend 4 follow-up sessions. 
 Consent to removing facial hair at the treatment site 
Exclusion criteria: 
 Metastatic disease 
 Previous radiation therapy to the head and neck area 
 Any skin conditions that can aggravate radiation-induced skin reactions 
 Karnofsky score<70 
 Patients living outside of Christchurch 
Participants were excluded if their Karnofsky score (80) was less than 70. This was because patients 
were required to apply the Sorbolene cream easily themselves. They also were required to fill in the 
patient component of the RISRAS scoring and come in each day for treatment, which would have been 
a struggle for patients with a score less than 70. 
 
2.3.2 Participant numbers 
The pilot in Christchurch aimed to recruit 20 patients over a 2 year period. As this is a pilot study to 
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established by a power calculation, but depended on  the number of patients who presented to the 
hospitals over the trial period. This thesis will only report on the analysis of the first 12 patients on the 
trial; six of whom were on the management protocol and six who were on the prophylactic protocol. 
 
2.3.3 Consent 
Patients were given verbal as well as written information about the trial in the form of a participant 
information sheet (Appendix C). This was done either at their CT scan (prophylactic protocol) –or day 
1 of treatment (management protocol) by the researcher. The patients were given the opportunity to 
discuss the trial information with whanau and were given the contact number of the researcher if they 
had any questions. Written informed consent was signed by the patients on the day of the first 
radiation treatment (prophylactic protocol) or a few days after their first day of treatment 
(management protocol) (Appendix D). Patients also consented to the use of photos for the trial, as 
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2.4 Treatment 
2.4.1 Radiation Treatment 
Treatment was given according to the department radiation therapy prescription guidelines. This is 
described in the following table (Table 2.1).  
 
Table 2.1. RT prescription guidelines for head and neck patients at Canterbury Regional 
Blood and Cancer Service.  
 
 
The planning technique, dose, the use of bolus and chemotherapy information was recorded for each 
patient (Table 3.1). All patients were treated in the supine position on a flat board that attached to 
the treatment couch. Each patient also had a thermoplastic mask made that reached done to their 




Patients who had stage III or IV disease also had chemotherapy at the same time as their radiation. 
This was with weekly IV cisplatin, 40mg/m2. Meta-analysis has shown a benefit of chemotherapy with 
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2.5 Intra-patient design, randomisation and blinding 
This was an intra-patient comparison where patients acted as their own controls, in order to remove 
potentially confounding factors such as treatment- and patient-related differences in skin reaction 
severity between patients (described in section 1.2). Any differences in skin reaction severity between 
skin covered in Mepitel Film or Sorbolene Cream are not likely to be due to treatment- and patient-
related factors in the cohort for this pilot study. This design also meant that all of the patients were 
able to experience what it is like to have Mepitel Film applied to their skin.   
 
2.5.1 Randomisation 
The control and intervention areas were divided into either inferior and superior halves or medial and 
lateral halves by the radiation therapy researcher. Mepitel Film was allocated randomly by pre-
prepared computer generated randomisation charts created by a Biostatistician at the University of 
Otago, Wellington. Randomisation removes allocation bias, ensuring that Mepitel Film is not allocated 
predominantly to the site that is likely to develop the least severe skin reactions. Mepitel Film was 
allocated to either superior/left or inferior/right depending on how the researcher divided the areas 
(see Figure 2.1). Randomisation was conducted via a randomisation form (Appendix E) which was sent 
by fax to the principal investigator Dr Patries Herst at the University of Otago, Wellington. The principal 
investigator had no direct involvement with the patients.  
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2.5.2 Blinding 
Blinding is important to reduce researcher and patient bias. This type of bias occurs when researchers 
and patients inadvertently score their preferred intervention more favourably than the other option. 
Unfortunately, the researcher and the patients in this pilot study were unable to be blinded. This is 
because the Mepitel Film stayed in place for many days and was very different in appearance than the 
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2.6 Procedure  
The intervention and control areas were drawn onto the patient with semi-permanent marker and 
were also transcribed onto a thin transparent mylar. The mylar included anatomical landmarks of the 
patient’s face to ensure the control and intervention areas could be accurately reproduced in case the 
drawn on marks or the Mepitel Film came off.  
 
2.6.1 Control area (Sorbolene) 
Dermasoft® Sorbolene cream contains Deionised Water, Glycerin, Cetearyl Alcohol, Mineral Oil, 
Ceteth 20, Polysorbate 60, Paraffin, Benzyl Alcohol, Methyl Paraben and Propyl Paraben and can be 
used as a moisturiser on sensitive skin (http://www.pharmacydirect.co.nz/Dermasoft-Sorbolene-
Cream-375g.html). Sorbolene does not contain sodium lauryl sulphate (SLS). All patients were asked 
to apply Sorbolene cream to the control area twice daily. Patients were advised to continue using the 
cream until moist desquamation occurred, at which point they were to cease using the cream and just 
use salt water bathing as per the department skin care guidelines (Appendix F).    
 
2.6.2 Intervention area (Mepitel Film) 
Mepitel Film consists of soft silicone webbing contact layer which adheres closely to the folds of the 
skin, complemented by a breathable transparent film. Mepitel Film was cut according to the mylar 
marks and applied to the area it was randomised to. Mepitel Film was applied to the patient’s neck in 
the extended position as this made it easier for the patient to move their neck once the Mepitel Film 
was applied. Dressings were replaced as needed. Mepitel Film was left in place for as long as possible 
but was replaced if it had significant peeling on the edges of the Mepitel Film. Mepitel Film was applied 
during treatment and for 4 weeks afterwards, as per the trial protocol. If moist desquamation occurred 
Mepitel Film was removed and patients were told to use salt water bathing as per the department 
skin care guidelines.  
 
Herst et al. (10) determined in a previous trial that Mepitel Film has a negligible bolus effect of 0.12mm 
and thus was left on during radiation treatment.  
 
2.6.3 Timing of the intervention  
Previous skin trials conducted in breast cancer patients showed that Mepitel Film is most effective 
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head and neck cancer patients is more complicated and individualised depending on the location and 
stage of the tumour. The dose to the tumour (and the skin) is higher and cisplatin chemotherapy is 
administered concurrently in many of the patients. It was expected that it would be difficult to predict 
where the worst reactions would occur and waiting till erythema developed would circumvent that 
problem. Therefore, the first six patients were enrolled on the management protocol.  
In addition, skin reactions are not necessarily the worst side effects of radiation therapy for these 
patients: oral mucositis is likely to have a more significant impact on patient quality of life (QoL). The 
team was expecting that patient compliance could be poor, because patients were likely to be very ill 
and because of the cohort demographics (older, often with substantial alcohol and tobacco usage). 
The researchers expected that compliance (and the motivation to use Mepitel Film) would be better 
if there was obvious erythema. Therefore the trial was started using the management protocol. After 
six patients, it became obvious that the results were disappointing and we changed over to the 
prophylactic protocol to try and decrease friction damage and thus improve the skin reaction reducing 
effects of the Mepitel Film. 
 
Management protocol 
At the first sign of erythema, the area was divided into 2 equal halves. It was decided that the halves 
had to be on the neck rather than the face in order to improve the adhesion of the Mepitel Film to the 
skin and increase patient compliance. One half was randomised to Mepitel Film, the other half was 
the control area randomised to Sorbolene cream.  The researcher checked each patient’s skin daily 
for erythema. Erythema was also verified against the Radiation Oncologist’s (RO) assessment in 
MOSAIQ, the patient management software system used at CRCHS.  
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On the first day of treatment, an area on the neck was selected from the treatment plan that had a 
relatively even dose distribution and was likely to get a dose of at least 40Gy to the skin. This area was 
divided into 2 equal halves. One half was randomised to be covered with Mepitel Film, the other half 
was the control area to be treated with Sorbolene cream. The area had to be at least 10cm by 5cm in 
order to adequately divide it into 2 equal study areas. The area also needed to have a relatively 
homogenous dose in order for the Mepitel and Sorbolene areas to receive approximately the same 
dose. This limited the areas that could be chosen significantly due to the nature of IMRT/VMAT plans 
used for treatment planning. This method of choosing the research area was not as accurate as the 
management protocol as the patient was not usually in exactly the same position as in the scan. 
However, the dose to the skin covered in Mepitel Film and cream was measured using TLDs to 
independently verify skin dose and determine whether or not differences in skin dose could potentially 
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2.7 Measurements 
2.7.1 Skin reaction severity 
The patient’s skin was examined each day until erythema occurred. Once erythema had developed, 
skin reaction severity was measured using the modified RTOG (60) and modified RISRAS (61,81) in 
both the control and intervention areas.  Scoring was done three times a week for the rest of the 
radiation treatment. After completion of treatment patients were seen once a week until 4 weeks 
after RT because skin reaction severity tends to peak after completion of treatment (42,74).  
 
The RISRAS scoring scale was used because of its high sensitivity; small differences in skin reaction 
severity will be evident that may not be evident in the more commonly used and less sensitive RTOG 
grading system. RISRAS was developed by Noble-Adams (61) and later modified by MacBride (81). The 
researcher component of RISRAS scores the visible stages of reaction (erythema, dry desquamation, 
moist desquamation or necrosis) separately and gives further details on the percentage of the area of 
affected skin. The modified RTOG scale allows for the distinction between brisk erythema and patchy 
moist desquamation which is lost in the original RTOG or CTCAE scales (82,83). The modified RTOG 
only determines the severity of the skin reaction severity and not the extent of the area affected.    
 
The RISRAS tool also includes a patient component, asking the patient to rate their level of discomfort, 
pain, itchiness, burning and the effect the skin reaction has on their day to day life, which allows for a 
more complete assessment of the patient experience. 
 
The modified RTOG scale was used in addition to RISRAS to enable direct comparison of the results of 
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Table 2.2. Skin reaction severity according to RISRAS and RTOG. 
RISRAS (total scores between 0 and 36)a 

















































Patient Component (total scores between 0 and 12) 
Symptoms Not at all A little Quite a bit Very much 
Is your skin in the treatment area tender, 
uncomfortable or painful? 
0 1 2 3 
Does your skin in the treatment area 
itch? 
0 1 2 3 
Do you feel any burning sensation on 
your skin in the treatment area? 
0 1 2 3 
Have your skin reactions and/or your 
symptoms affected your day to day 
activities? 
0 1 2 3 
 
Modified RTOG 
 Grade 1 Grade 1.5 Grade 2 Grade 2.5 Grade 3 Grade 4 
Follicular, 
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2.7.2 Skin dose 
The research area was to receive a homogenous high dose (>35Gy). This was determined using 
planning software to extrapolate the dose to the skin, which only gives an approximation of dose and 
not an absolute dose. Because total dose is such an important factor in skin reaction severity and thus 
a potential confounder in this study, the actual dose to the Mepitel Film and Sorbolene treated skin 
was determined for each patients, using thermoluminescent dosimeters (TLDs). For each patient a set 
of 3 TLDs were placed in the centre of the control and intervention areas (see figure 2.4).The TLDs 
were provided and measured courtesy of the Southern DHB Oncology and Haematology Service. An 
average dose was taken from these TLDs to determine the dose delivered to the control and 
intervention areas of the skin. These were labelled as Mepitel Film or Aqueous cream TLDs, as that 
was what they used in a previous study(10). As stated previously, Sorbolene cream was the actual 
control cream used in this cohort. 
 
Figure 2.4 Photo of Mepitel and Sorbolene areas TLDs for patient CRT-01. 
 
2.7.3 Distress levels 
There is some evidence that increased cortisol levels due to stress can delay wound healing (43,47,48). 
A distress screening tool for oncology patients was first developed by the National Comprehensive 
Cancer Network specific for oncology patients. An impact thermometer was developed and added to 
the tool by Akizuki et al. (79,84). The tool consists of two thermometers that the patient uses to rank 
their perceived distress levels in the last week (on a scale of 0-10) and what impact that has had on 
their life (from 0-10). This distress tool also features different types of stressors in 5 domains (spiritual, 
practical, family, emotional and physical). The patient then indicates by ticking a series of boxes within 
these domains to indicate which of these potential stressor have affected them in the past week 
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2.7.4 Exit questionnaires 
Patients were given an exit questionnaire asking about their experience of being on the trial and the 
advantages or disadvantages of the Mepitel Film on completion of their follow-up period of 4 weeks. 
11 out of 12 patients completed the questionnaire (Appendix H). 
 
Endpoint 
Because Mepitel Film is permeable to gases but no to moisture, moist desquamation was the endpoint 
of this trial. Patients who developed moist desquamation were treated according to departmental 
guidelines. 
 
Withdrawal from the study due to adverse events 
Mepitel Film and Sorbolene cream are both relatively hypoallergenic and do not contain any 
components known to have a harmful interaction with the skin. If a patient develops an intolerance 
to either product, substitution will be at the Oncologist’s discretion. In the event of intolerance the 
patient would be withdrawn from the trial but the information gathered would still be part of the final 
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Chapter 3  Results 
3.1 Patient recruitment 
This analysis includes patients recruited from December 2014 to December 2015 at the Canterbury 
Regional Blood and Cancer Service. The consort diagram below (Figure 3.1) summarises the accrual 
process.  During this period 31 patients were screened for eligibility. Thirteen of these lived in another 
region and thus were excluded because they were unable to attend the follow-up appointments.  
Three patients were deemed unacceptable for inclusion by the oncologist. The first patient had poor 
health literacy and poor English. Another patient was extremely anxious and required medication. The 
third patient was unable to speak or read well making consent difficult.  One patient was only having 
radiation to the face and this was not deemed appropriate for trial inclusion. One patient was not 
interested in participating.  The remaining 13 patients were given written and oral information about 
the trial when they came for their CT scan. This allowed at least ten days for the patient to discuss trial 
involvement with their friends and family if they wished to. The researcher saw the patients again 
during the first two days of their treatment where the patients signed the consent form and were 
randomised. One of these patients kept applying Sorbolene cream in the Mepitel area, resulting in the 
Mepitel falling off, and thus was excluded from analysis due to non-compliance. The first 6 patients 
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Figure 3.1. Consort Diagram: flow of patients through the trial. 
3.2. Patient demographics 
A total of 13 patients were recruited into the study between 27th December 2014 and 30th December 
2015. Results from the 12 fully compliant patients were used in this analysis. The patient 
demographics are shown in Table 3.1. The cohort consisted of ten men and two women with an 
average age of 59 years (range 40-83 years). Most patients (n=10) identified as New Zealand European 
descent, with two patients identifying as Maori.  Most patients (n=11) received 66Gy in 30 fractions 
using an inverse planning technique (IMRT and VMAT) because of the advanced disease stage (III or 
IV); whereas the only 3DCRT patient had stage I disease.  With respect to HPV status; eight of the 12 
participants’ tumours tested positive, one tested negative, and the remaining three patients’ tumours 
were not tested for HPV status. Baseline information was obtained from each patient with regard to 
smoking, alcohol use and diabetes status.  A total of seven out of 12 patients had a history of smoking.  
The Fitzpatrick skin type scale (Appendix I, (85) )was used to assess skin type. The majority of patients 
had skin type III. None of the patients had diabetes. One patient had bolus with 3DCRT planning. Eight 
out of the twelve patients also had concurrent chemotherapy as part of their treatment. Patient 
numbering was done according to if they had chemotherapy and radiation therapy (CRT), or radiation 
therapy alone (RT) 
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Table 3.1 Patient Demographics 
Patient ID protocol Primary Stage Sex Dose RT HPV Age BMI Ethnicity Smoker Sun Skin type 
CRT01 Management Oropharynx IVB M 66 IMRT + 52 28.2 Maori ex often VI 
CRT02 Management Rt glottis I M 63 3DCRT unknown 56 27.5 NZ Eur ex often III 





III F 60 IMRT negative 55 22.5 NZ Eur ex often III 
CRT06 Prophylactic Tonsil IVA M 66 VMAT + 63 21.5 Maori Y rarely IV 
CRT07 Prophylactic Tonsil IVA M 66 IMRT + 56 26.9 NZ Eur ex often IV 
CRT08 Prophylactic Tongue IVA M 66 VMAT + 57 24.3 NZ Eur N often III 
CRT09 Prophylactic Left tonsil IVA M 66 VMAT + 58 22 NZ Eur N rarely III 
RT01 
Management Base of 
tongue 
IVA M 66 IMRT + 52 29 NZ Eur N rarely III 
RT02 Management Lower gum IVA M 60 IMRT unknown 72 21.8 NZ Eur ex Often IV 
RT03 
Management Skin of lip 
(mets in neck 
nodes) 
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3.3. Dose to the skin 
Because the dose to the skin is the main factor in skin reaction severity and therefore a possible 
confounder in this trial, the dose to the skin underneath Mepitel Film and Sorbolene control cream 
was measured for each patient, using TLDs (see Table 3.2). Unfortunately, the same set of TLDs was 
used for both CRT04 and RT04 and thus the dose data from these two patients could not be used in 
this analysis. There was a 1Gy increased mean dose to the skin in the Mepitel Film area (50.95Gy) 
compared to the control area (49.43Gy).  This was not statistically significant (p= 0.137, student t-test). 
It is therefore unlikely that skin dose would have affected skin reaction severity or the incidence of 
moist desquamation.  
 
Table 3.2 TLD dose to Mepitel and control (Sorbolene) areas. 
  Dosimetry (Gy) 
Patient ID Mepitel Control 
CRT01 57.17 53.83 
CRT02 48.99 48.92 
CRT03 50.76 50.28 
CRT04     
CRT06 52.11 52.5 
CRT07 51.03 47.94 
CRT08 50.26 44.19 
CRT09 46.14 49.48 
RT01 48.43 49.26 
RT02 49.19 43.82 
RT03 55.38 54.12 
RT04     
Ave 50.95 49.43 
SD 3.28 3.54 
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3.4 Skin reaction severity 
 
3.4.1. Average RISRAS scores 
RISRAS scores were compared between the Mepitel Film and the Sorbolene control areas for both the 
management (Figure 3.2; Tables 3.3 and 3.4) and prophylactic (Figure 3.3; Tables 3.3 and 3.5) 
protocols. The researcher, patient and combined scores were analysed.  A paired two-tailed T test was 
used to evaluate whether the differences were statistically significant. A p value of less than 0.05 was 
used as the threshold for statistical significance. Figure 3.2 visualises differences between both 
protocols. 
 
Table 3.3 Individual break down of RISRAS scores of all patients.* 
 
 Average RISRAS scores 
  Mepitel Film Sorbolene 
  Combined Researcher Patient Combined Researcher Patient 
CRT01 3.78 2.33 1.44 4.5 2.56 1.94 
CRT02 1.4 1.1 0.3 3.45 2.15 1.3 
CRT03 4.92 2.85 2.23 6.12 3.12 3.00 
RT01 3.2 2.47 0.73 4.57 2.77 1.8 
RT02 1.55 1.36 0.18 2.09 1.55 0.55 
RT03 4.15 3.23 0.92 5.92 3.62 2.23 
CRT04 3.09 2.09 1.00 6.44 2.15 4.29 
CRT06 1.92 1.83 0.08 2.42 2.08 0.33 
CRT07 5.77 2.69 3.08 8.15 3.65 4.50 
CRT08 2.81 2.35 0.38 2.77 2.31 0.38 
CRT09 2.14 1.93 0.21 2.64 2.43 0.21 
RT04 1.96 1.88 0.08 3.73 2.50 1.23 
Averages 3.06 2.18 0.89 4.40 2.57 1.81 
SD 1.38 0.61 0.94 1.91 0.63 1.48 
SEM 0.39 0.17 0.27 0.54 0.18 0.42 
p-values  0.001 0.002 0.004    
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Table 3.4 Average scores of the six patients on the management protocol. 
  Average RISRAS scores 
  Mepitel Film Sorbolene 
  Combined Researcher Patient Combined Researcher Patient 
Averages 3.17 2.22 0.97 4.44 2.63 1.80 
SD 1.43 0.83 0.77 1.52 0.73 0.83 
SEM 0.58 0.34 0.31 0.62 0.30 0.34 
p-values 0.003 0.029 0.002    
 
 
Table 3.5 Average scores of the six patients on the prophylactic protocol. 
 Average RISRAS scores 
  Mepitel Film Sorbolene 
  Combined Researcher Patient Combined Researcher Patient 
Averages 2.95 2.13 0.81 4.36 2.52 1.83 
SD 1.46 0.33 1.16 2.38 0.58 2.02 
SEM 0.73 0.17 0.58 1.19 0.29 1.01 




Figure 3.2 Graphs showing the combined average RISRAS scores for the management (A) and prophylactic (B) cohorts. 
 
When the results of all patients were combined, there was a statistically significant decrease in skin 
reaction severity in favour of Mepitel Film of 29% for combined scores, of 15% for researcher scores 
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reaction severity was also statistically significant for combined (30%), researcher (16%) and patient 
(52%) RISRAS scores. For patients on the prophylactic protocol there was a statistically significant 
reduction in skin reaction severity for the combined (28%) and researcher (14% scores) in favour of 
Mepitel Film. This decrease was of border line significance for the patient scores (46%). The large 
variation in patient scores responsible for this lack of statistical significance was due to two patients 
with moderate skin reactions who reported that Mepitel Film did not make any difference to their skin 
at all. In such a small cohort this affected the SEM and the p value for the patient RISRAS score. When 
both management and prophylactic protocol patients were combined this effect was no longer 
evident. Figure 3.3 and 3.4 show the effect Mepitel had on the skin compared to the Sorbolene area 
in two patients. 
 
 
Figure 1.3 patient CRT07 last day of treatment 
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3.4.2. Peak RISRAS scores 
The peak RISRAS scores refer to the maximum recorded researcher score from any assessment in the 
study areas. For the majority of patients, the peak score occurred at the end of treatment or in the 1-
2 weeks following treatment. The difference in peak RISRAS score between skin covered with Mepitel 
Film and control skin was significantly different (p=0.02) (Student t-test) in favour of Mepitel Film 
(Table 3.6). 
 
Table 3.6 Peak Researcher Scores for each patient. 
 Peak Researcher RISRAS Score 
Patient ID Sorbolene Mepitel 
CRT-01 7.5 4 
CRT-02 4.5 2 
CRT-03 6.5 6 
CRT-04 4 5 
CRT-06 6 4 
CRT-07 7.5 5 
CRT-08 7 8.5 
CRT-09 4 3 
RT-01 6 3 
RT-02 3 2 
RT-03 9 9.5 
RT-04 9 6.5 
Average 6.17 4.88 
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3.4.3. Modified RTOG 
 
Table 3.7 displays the peak modified RTOG scores for all trial patients. The clinically most significant 
difference is between 2 (brisk erythema) and 2.5 (moist desquamation).   
 
Table 3.7. Peak RTOG scores for each patient. 
 RTOG Peak Score 
Patient ID* Mepitel  Control  
CRT01 2 2.5 
CRT02 2 2.5 
CRT03 1 2.5 
RT01 2 2.5 
RT02 1.5 1.5 
RT03 3 2.5 
CRT04 2.5 2.5 
CRT06 2 2 
CRT07 2 2.5 
RT04 2.5 2.5 
CRT08 3 2.5 
CRT09 2 2 
# with 1 and 1.5 2 1 
# with 2 6 2 
# with 2.5 2 9 
# with 3 2 0 
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3.4.5. Incidence of moist desquamation 
The incidence of moist desquamation in the trial areas was assessed in the research areas both by the 
researcher part of RISRAS (as % of skin area with moist desquamation) and RTOG (level IIB and above) 
(Table 3.7). Any areas outside of the test areas that developed moist desquamation were not included 
in any analyses. Overall when RTOG scores are compared between Mepitel Film and control patches 
for all patients, 4 patients (33%) developed moist desquamation in the Mepitel areas and 9 patients 
(75%) developed moist desquamation in the control areas. 
 
Management protocol 
For the management protocol 17% of the Mepitel Film areas (n=1) developed moist desquamation 
compared to 83% (n=5) of the control areas.  The patient that developed moist desquamation in the 
Mepitel Film area received a slightly higher dose in that area compared to the control area.  Patient 
CRT02 was the only patient where the entire treatment fields were included in the Mepitel Film and 
control areas. This is because this patient had a low stage of disease so the fields encompassed a very 
small area.  
 
Prophylactic Protocol 
For the prophylactic protocol, 50% of the patients developed moist desquamation in the Mepitel Film 
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3.4.6. Time to peak skin reaction 
The peak reaction was defined as the peak researcher RISRAS score for each patient. The time to the 
peak reaction was calculated as days from the start of treatment (Table 3.8). For the Mepitel Film 
areas, the mean time to peak skin reaction was 41.5 days (range 33-48) and 38.1 days (range 27-46) 
for the Sorbolene control areas. On average, the peak reaction under the Mepitel Film took 3.4 days 
longer to occur.  Using a paired sample two-tailed student t-test, this difference was shown to be 
statistically highly significant (p=0.001).  
 
Table 3.8 Time in days to the peak reaction for each patient. 
 Time to Peak Reactions (Days) 
Patient ID Mepitel  Sorbolene 
CRT-01 46 46 
CRT-02 47 42 
CRT-03 46 40 
CRT-04 39 35 
CRT-06 43 37 
CRT-07 33 27 
CRT-08 39 35 
CRT-09 38 35 
RT-01 38 38 
RT-02 37 37 
RT-03 48 41 
RT-04 44 44 
Average 41.5 38.1 
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3.5 Stress levels 
 
Patient stress levels were measured using the NZ validated Distress Thermometer (DT)(79). Maximum 
reported stress levels, the stages of the treatment these occurred at, maximum skin reaction severities 
and the presence of moist desquamation (MD) are reported in Table 3.9. The mean maximum stress 
score was 7 and the mean time from the start of RT to maximum stress was 43 days. Patient RT-01 
reported he did not suffer from stress at any time of his treatment, scoring a 1 for all assessments. 
Patients CRT-02, CRT-04 and CRT-08 each reported a score of 10, the highest level of stress. The 
National Comprehensive Cancer Network (NCCN) suggests that the best cut-off point for non-
stressed/stressed individuals is 3/4(86). If we follow those guidelines, all but patient RT-01 should be 
considered stressed and an evaluation of stress on skin reaction severity would not be possible. The 
one patient who did not consider himself stressed developed MD; whereas patients who scored “5” 
“7” and “8” did not develop MD. 
 
Table 3.9 Peak stress and RISRAS scores, time to peak scores and presence of moist 









Time to peak 
RISRAS (days) 
MD 
RT-01 1 1 6 38 yes 
RT-03 4 22 9 41 yes 
CRT-01 4 32 7.5 46 yes 
RT-02 5 44 3 37 no 
CRT-03 7 46 6.5 40 yes 
CRT-06 7 37 6 37 no 
CRT-07 8 16 7.5 27 yes 
CRT-09 8 43 4 35 no 
CRT-02 10 42 4.5 42 yes 
CRT-04 10 46 4 35 yes 
CRT-08 10 39 7 35 yes 
RT-04 10 38 9 44 yes 
Average 7.0 34 6.2 38   
SD 3.0 14.0 2.0 5.0   
SEM 0.9 4.0 0.6 1.5   
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Plotting maximum stress levels against maximum researcher RISRAS levels (Figure 3.2A), or time to 
peak stress scores against time to peak RISRAS scores (Figure 3.2B) shows no correlation between 
stress levels and skin reaction severity. 
 
Figure 3.2. Lack of correlation between stress levels and skin reaction severity. A. Correlation 
between peak scores of individual patients. B. Correlation between time to peak scores of individual 
patients. 
 
The number of times each area of concern was reported over the study is documented in Table 3.10). 
The most common concerns were mouth sores (n=35) pain (n=31) and fatigue (n=30). Patients also 
commented on ‘other’ areas not listed on the stress thermometer. These included having to wear a 
mask during treatment, throat pain, vomiting, moving house, coughing, swallowing and being in 
hospital. Three patients commented on their frustrations with treatment. Six patients were admitted 
to hospital for various reasons, including nausea, hydration, chest infection, bilateral pulmonary 
emboli, neutropenic sepsis and low platelet count.  
 
Table 3.10 Areas of concern for patients that contributed to their perceived distress.  
Domains Area of concern Times reported 
Spiritual  0 
Practical Child care 0 
 Housing 0 
 Financial  1 
 Transportation  1 
 Work/school 4 
 Cultural obligations 0 
 Hospital processes 1 
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 Dealing with partner 12 
 Other family members 4 
 Family dealing with the situation 5 
Emotional Depression 5 
 Fears 9 
 Anxiety 12 
 Sadness 5 
 Worry 11 
 Loss of interest in usual activities 15 
Physical Appearance 3 
 Bathing/dressing 1 
 Breathing 3 
 Urination 2 
 Constipation 12 
 Diarrhoea 12 
 Eating 33 
 Fatigue 30 
 Feeling swollen 3 
 Fevers 2 
 Getting around 3 
 Indigestion 1 
 Memory/concentration 5 
 Mouth sores 35 
 Nausea 18 
 Dry nose/congested 9 
 Pain 31 
 Sexual 1 
 Skin dry/itchy 12 
 Sleep 8 
 Tingling hands/feet 1 
Other Mask 1 
 Mask+waiting for treatment 1 
 Coughing 1 
 Vomiting 1 
 Pain in tongue 1 
 Moving house 1 
 Being in hospital, swallowing 1 
 Frustrated with treatment, secretions 1 
 Throat phlegm and cramps 1 
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Not being able to be my normal self is 
frustrating 
1 
3.6 Exit questionnaires 
 
Each patient was given an exit questionnaire to give them the opportunity to describe their experience 
of being in the trial and using Mepitel Film and Sorbolene on their skin at the end of the follow-up 
period. A total of 11 out of 12 patients returned the questionnaire.  
 
Trial experience 
Ten patients answered the question about whether being in the trial was a positive experience or not 
with “yes”. The patient who answered this question with “no”. Five patients commented about their 
experience, with a clear theme of altruism as a reason for participating.  
“good to know it may make a difference to someone”- CRT04 
“happy to help”- RT01 
“good to be seen weekly’ by the research assistant”- CRT09 
“yes it was a positive experience”- CRT01 
“yes Hayley (the research assistant) is very competent”- CRT07 
It appeared that the patients appreciated being seen by a designated person, as the research assistant 
often helped the patient with side effects other than skin reactions. 
 
Managing skin reactions 
When asked whether Mepitel was better than Sorbolene in managing their skin reactions, nine out of 
11 patients answered that they thought the Mepitel Film was better than the cream. The remaining 
two patients did not answer this question.  Two patients commented that the Mepitel Film helped 
reduce itching and irritation and one patient commented that there was less skin flaking under the 
Mepitel Film.  
 
Mepitel helped “stop the itching and irritation’ – CRT02 
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In the management group patients commented that the Mepitel Film helped more during the 
treatment, but during the follow-up period the cream patch seemed to heal faster.  
 
“At the peak of the treatment when it was burning the film was good but when the other side 
has healed the film side is itchy and worse’ – CRT01 and another said ‘possibly, however the 
Sorbolene was very good at soothing the skin reaction and seem to be better at the end; ie 
Sorbolene side recovered faster”- RT01 
 
Advantages of Mepitel Film 
When asked about what were the advantages of using Mepitel Film, all 11 patients answered this 
question. The patients commented on the ease of use and comfort of the Mepitel Film.  
 
“There was no burning, stinging or itching”- CRT04  
”didn’t get the burning feeling like the rest of my neck”  - RT04 
 
Two patients commented that Mepitel Film was better at the beginning of their treatment. 
 
“Mepitel was good at the peak of burning but after that it was too itchy”- CRT01 
“Mepitel seems to be better at the beginning” – RT01 
 
Disadvantages of Mepitel Film 
When asked about the disadvantages of using Mepitel Film, nine patients answered this question. The 
majority of patients agreed that the Mepitel Film often came off easily and rolled at the edges, which 
was annoying to them. 
 
“Only slightly annoying when it wouldn’t stay on. Appearance not an issue for me”- RT01  
 
Patient CRT02 commented during the treatment that he was asked by work colleagues ‘why he had 
glad wrap on his face’. The patient however stated he was not bothered by these questions.  
One patient commented that Mepitel Film had 
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Another patient felt that the disadvantage was that he didn’t get to use the Mepitel Film everywhere. 
 
“….more comfortable – didn’t get the other symptoms like the rest of my neck- would have 
liked Mepitel over the whole neck”- RT04 
 
 
Taking part in other clinical trials in the future 
Ten patients said they would be happy to take part in future clinical trial based on their experience 
with this trial. Again the theme of altruism was noted, with patients commenting  
 




 ‘yes I would because it’s helping other people.’ – RT04 
 
 
Results of the trial 





  4074137 
49 | P a g e  
 
Chapter 4 Discussion 
 
The aim of this randomised controlled feasibility study was to investigate whether Mepitel Film 
dressings were superior to Sorbolene cream in reducing or managing radiation-induced skin reactions 
in patients with head and neck cancer. Based on previous studies in breast cancer patients (10), it was 
hypothesised that Mepitel Film would protect the irradiated skin from friction and thus further 
damage. This thesis has analysed the skin reactions of first 12 patients of a larger feasibility trial and 
includes six patients on the management protocol and six patients on the prophylactic protocol at the 
CRCHS. The feasibility study is now closed for further recruitment in NZ and is still recruiting in China. 
 
Mepitel Film was tested against Sorbolene cream. This is not the standard of care at CRCHS, which 
instead uses Fatty E cream. Fatty E cream and Sorbolene cream are similar emollients and neither 
contain sodium lauryl sulphate, which has been shown to thin the skin (62,63). Sorbolene cream was 
chosen based on the review by Kumar et al., as it is a common emollient used throughout Australia 
and New Zealand (9). Emollient creams are also recommended by over 70% of departments who 
responded to their survey, so using Sorbolene cream was therefore considered a clinically relevant 
control cream. None of the patients experienced any adverse events due to Mepitel Film. Mepitel did 
not cause any allergic skin reaction for any of the participants.  
 
A discussion of the key findings is provided below, followed by a discussion of limitations and 
suggestions for future research. 
 
4.1   Skin reaction severity  
 
Based on the theory that Mepitel Film is a completely inert dressing, which closely adheres to the skin 
to provide protection against friction, it could be assumed that the sooner Mepitel Film is applied, the 
better it works. This theory can be substantiated when comparing the moist desquamation  (MD) 
incidences between the prophylactic Mepitel Film trial by Herst et al. (10), the No-Sting Barrier Film 
by Graham et al. (74) and the management Mepilex Lite trial by Paterson et al. (42). Herst et al. used 
Mepitel Film in both mastectomy (n=44) and non-mastectomy (n=34) breast cancer patients from the 
start of radiation therapy and found an overall decrease in skin reaction severity of over 90% in the 
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compared with MD rates in control patches of 27% (10). Graham et al. found a reduced rate of moist 
desquamation in their mastectomy cohort, with 33% for the No-Sting Barrier Film vs 46%  for 
sorbolene (p=0.096) and for all patients with area under the curve skin toxicity using RTOG was 
reduced (8.1 vs 9.2, p=0.005). They also got patients to score pruritus and pain on a 5 point Likert 
scale, with a significant change favouring No-Sting Barrier Film for pruritus (area under the curve, 
p=0.011). In sharp contrast, Paterson et al. who used Mepilex Lite from the moment erythema was 
visible in 74 post-mastectomy patients reported an overall decrease in skin reaction severity of 40% 
but no statistically significant difference between MD rates of skin covered in Mepilex Lite and skin 
covered in control cream. This trial was conducted in four different centres and reported an average 
MD rate over all four centres of 47% (42). The superior results of the prophylactic trial over the 
management trial are due to a number of factors:  
 Friction protection is going to be most useful when used prophylactically rather than wait till 
radiation damage to the skin in obvious (when erythema is visible). Hence MD rates in prophylactic 
trials should always be lower than in management trials if the intervention works by providing 
friction protection. 
 Total dose to the skin is arguably the most important determinant of skin reaction severity, with 
friction protection less likely to prevent MD at higher skin doses up to the point that the total dose 
becomes lethal to the basal skin cells and MD is unavoidable. Average skin doses for patients in 
the prophylactic Mepitel Film breast trial(10) ranged from 30Gy to 39Gy (depending on location) 
for patients on the conventional regimen (MD 41%) and between 24Gy and 30Gy for patients on 
the hypo-fractionated regimen (MD 17%). The lower skin dose resulted in a lower MD rate in this 
trial. 
The trials used different dressings. Cavilon No-Sting Barrier Film contains an organosilicon 
compound that starts as a liquid but becomes a film on contact. Mepitel Film and Mepilex Lite 
both have a soft silicone contact layer (Safetac technology) which mediates the friction protection 
of these dressings. Mepitel Film is thinner and transparent and sticks better, can be left on during 
radiation and thus can be used in a prophylactic setting. Mepilex Lite is thicker with a thin non-
transparent foam layer on top of the silicon contact layer and needs to be removed during 
radiation. It could be that Mepitel Film would provide better protection from friction because it 
conforms better to the folds of the skin and is more likely to stay on the skin for longer, before 
needing to be replaced.  
In light of the breast cancer trial results, the results of the 12 head and neck cancer patients analysed 
for this thesis were very interesting and not altogether unexpected because of the higher skin dose 
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1. Mepitel Film reduced skin reaction severity 
Mepitel Film reduced the combined, researcher and patient components of RISRAS for patients in 
both the management and prophylactic protocols. This decrease in skin reaction severity was 
statistically significant for differences in RISRAS scores of patients on the management trial (p values 
of 0.001, 0.002 and 0.004 respectively) and statistically significant for the combined and researcher 
component and trending towards significance for patients on the prophylactic protocol apart (p values 
of 0.021, 0.023 and 0.058 respectively). Skin reactions peaked on average 38 days after the start of 
radiation therapy for control patches and after 41.5 days for Mepitel Film patches. This compares well 
with skin reaction peak times reported by the prophylactic Mepitel Film breast trial (35 days) (10) and 
the management Mepilex Lite breast trial l (40 days) (42). Although significant, the decrease in skin 
reaction severity (and hence the amount of protection provided by) Mepitel Film was disappointing 
(decrease in combined RISRAS of 29%) compared to the decrease reported in breast cancer patients 
(91%).  
 
2. Patients liked Mepitel Film 
The patients, who scored the extent of pain, burning itchiness and effect on daily life, rated Mepitel 
Film higher (50% decrease) than the researcher (16% decrease) who scored the visible skin reactions 
(erythema and desquamation). Because the patient and researcher component contribute equally to 
the combined (overall) RISRAS score, the patient component has a very large impact on the overall 
skin reaction score (29% decrease). The breast management trial by Paterson at al also documented 
a stronger positive score from the patients (66% decrease) compared to that of the researchers (28% 
decrease), resulting in an overall decrease for Mepilex Lite of 41%. One could argue that the driving 
force behind running radiation-induced skin trials is to find the best way to prevent or manage skin 
reactions because they affect patient quality of life. The patient component is part of assessing the 
effect of the dressings on patient quality of life and as such carries a certain amount of weight in these 
trials. In support of this, patients mentioned in the exit questionnaire that “Mepitel ‘didn’t get the 
burning feeling like the rest of my neck” (RT04).  
 
3. Skin reaction severity was similar between management and prophylactic protocols 
Moist desquamation rates for Mepitel Film patches were lower for management protocol patients 
than prophylactic protocol patients (17% and 50% respectively). In contrast, control moist 
desquamation rates were higher for management protocol patients than prophylactic protocol 
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these cohorts were very small. However the trends discussed here for the 12 patient cohort are the 
same as for the slightly larger feasibility trial. The results indicate that there is no obvious benefit in 
applying Mepitel Film from the start of radiation therapy compared with applying it when erythema 
has developed.  
 
Does this mean that the protective effect of Mepitel Film is lost in the first few weeks of radiation 
therapy before erythema develops? Perhaps this question is best answered by a careful scrutiny of 
the head and neck cohort, which consisted of nine men and three women. Early on in the study it 
became very clear that the continued growth of stubble on the men’s necks prevented Mepitel Film 
from adhering to the folds of the neck. Although silicone based adhesives have many contact points 
even over uneven surfaces (87), dryness, sweating and hair in the area does affect their adhesion (87). 
As epilation occurs at approximately the same time as erythema develops (21), it is likely that the 
protection of Mepitel Film was non-existent during the first few weeks of radiation therapy for these 
men, explaining the lack of difference in skin reaction severity in the prophylactic and management 
protocols. The review by Russi et al. also mentioned that Mepitel Film may be difficult to use in head 
and neck cancer patients, due to the increase in skin folds in this area (7). In addition, the only woman 
on the prophylactic protocol had greater benefit from Mepitel (25% decrease in researcher RISRAS) 
than the two women on the management protocol (9% and 3% decrease in researcher RISRAS). The 
numbers of females in the study is too small to do a meaningful subgroup analysis of these patients. 
Recruiting females into a head and neck study is difficult as men dominate this cohort with a male to 
female ratio of 4 according to the New Zealand Cancer Registry (88). Although a previous study has 
reported that female patients are at greater risk of severe radiation toxicity (38), a larger study with 
more patients is required to validate this using Mepitel Film.  
 
4. Head and neck patients have a higher incidence of moist desquamation. 
Moist desquamation rates for controls in both the prophylactic (67%) and management (83%) 
protocols were higher than those reported for the breast cancer trials (26% and 47% in prophylactic 
and management protocols).(10,42) 
 
Taken together, these results show that Mepitel Film is less effective in head and neck cancer patients 
than in breast cancer patients. The most likely explanation is that the skin dose in head and neck 
patients was much higher compared with breast cancer patients. The average skin doses were 51Gy 
for Mepitel Film skin patches (52Gy for management protocol and 50Gy for prophylactic protocol) and 
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differences between Mepitel Film and control patches and management and prophylactic protocols 
were not statistically significant and are unlikely to have contributed to any differences in moist 
desquamation rates or overall skin reaction severity. However, these skin doses are a lot higher than 
for the prophylactic Mepitel Film breast trial(10) with average skin doses less than 40Gy, which will 
have contributed to the higher moist desquamation rates in the controls. The substantially higher dose 
may also have contributed to the higher desquamation rates in the Mepitel Film skin patches. It is 
possible that these higher doses cause too much damage to the skin and that protection against 
additional friction is less effective than at lower doses where the skin is able to repair itself in the 
absence of additional friction damage. A clear dose response relationship between skin reaction 
severity and dose to the skin has been described previously (23). 
 
The skin area in the neck may also be tougher than skin in the breast/chest area because it is more 
exposed to the weather and possibly dryer and more wrinkled in older patients (average age in 59 
years: range 40-83 years). In addition, regular shaving will “toughen” the skin. Perhaps the protective 
effect of Mepitel Film is not as pronounced in tougher skin that is exposed to friction from clothing. 
However, skin in the neck may be more prone to moist desquamation because of the stretching of the 
skin to accompany movement of the head. In the previous Mepitel Film trial, most MD occurred in 
areas of increased moisture and friction such as the axilla and inframammary skin folds (10). Skin of 
the head and neck area is also far more likely to have experienced previous sun exposure than the 
breast. A study using reflective spectrophotometry however showed that areas of higher sun exposure 
just showed higher baseline erythema readings compared to irradiated sites and not the highest 
change in erythema readings (89), whereas Porock et al. hypothesised that UV radiation thins the 
epidermal layer of the skin or can impair the inflammatory phase of healing (16). 
 
Other studies have reported Grade 3 or higher skin reactions for head and neck cancer patients 
planned using IMRT as low as 7.5%(24,27). These reports however did not discuss the absolute rate of 
moist desquamation in their patients but rather used the RTOG scale. Grade 2 on the RTOG scale can 
be brisk erythema or patchy moist desquamation so just reporting levels of grade 3 skin reactions does 
not provide a comprehensive evaluation of skin reaction severity. A retrospective analysis of 104 head 
and neck cancer patients by Givens and colleagues recorded grade 3-4 skin reactions as between  
25.7% and 29.6% depending on the IMRT protocol used (90). Only two patients (16.7%) in this study 
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4.2 Stress levels 
An interesting finding from the Mepitel Film breast cancer trial was that women who were more highly 
stressed had more severe skin reactions.(91) At every assessment (3x a week), women were asked a 
standard set of questions about how they were feeling, sleeping, eating, hydrating, managing family, 
work and other aspects of their lives such as their perceived stress levels. A simple LIKERT scale was 
used to score patients from 1 (very well) to 5 (not well at all). A highly stressed person was defined as 
someone with three scores of 5 for each of at least two questions. Using these criteria, 20 patients 
(26%) of the predominantly female breast cohort (n=78) were deemed stressed and a comparison of 
RISRAS scores between the stressed and non-stressed cohorts showed significantly worse (2x) skin 
reactions in the stressed cohort, with a 5x higher change of developing moist desquamation.(91)). In 
this trial the researcher wanted to assess if stress was a contributing factor in the predominantly male 
head and neck cancer cohort. Instead of using a non-validated stress measure, this trial used the 
validated NZ Distress Thermometer (79). Interestingly, if the NCCN guidelines for analysis of Distress 
Thermometer data are followed, all but one of the patients in this cohort were stressed and the only 
patient who did not considered himself stressed at all, developed moist desquamation. Three of the 
stressed patients did not develop moist desquamation. Correlational analysis showed no direct 
correlation between stress levels and skin reaction severity in this head and neck cohort.  
 
The areas for concern for these patients were all related to oral mucositis: mouth sores (35 times) 
problems with eating (33 times) and pain in the oral cavity (31 times). Skin dry/itchy was only reported 
12 times. Patients in this trial were often hospitalised  for chest infections, pulmonary emboli or 
hydration and pain issues.  This is consistent with a trial by Givens et al., where  97.1% of head and 
neck patients developed oral mucositis compared to 25.7% developing moist desquamation using 
IMRT(90). In their study, 25.7% of patients developed severe dehydration or malnutrition and the 
same number developed severe nausea and vomiting. Although skin reactions have been reported to 
be distressing for breast cancer patients (92), head and neck cancer patients have much more 
challenging side effects that can contribute to their perceived stress. Although one could argue that 
managing skin reactions may not be as important as managing oral mucositis as it was reported less 
often by this patient cohort, one could also say that finding an easy way to decrease skin reaction 
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4.3 Limitations 
The main limitation of this trial is the unavoidable lack of blinding because the intervention is a film 
and the control is a cream. This may have caused some researcher and participant bias when assessing 
skin reaction severity. When asking patients to assess the Sorbolene control and Mepitel Film areas, 
some patients found it difficult to differentiate between the two areas. Due to the complex nature 
and rapid dose falloff of IMRT and VMAT plans, the control and Mepitel Film areas were often chosen 
on the same side of the neck, as the opposite side tended to have a different dose depending on the 
site of diagnosis. It was not possible like the breast cancer trial to completely separate the treatment 
field into two equal halves for most patients. Patients would often comment on how the contralateral 
side of their neck felt rather than the same side.  
 
Other limitations included: 
 The study areas did not include the entire treated area, due to the complex nature of VMAT 
and IMRT plans. One patient had a 3DCRT plan that were able to be divided into equal halves 
for the study and made assessing the area for both the research assistant and the patient 
much easier. For the other patients, the side of the neck with the most even dose according 
to the planning system was chosen, meaning the study areas were not necessarily the area of 
highest dose. This made it difficult for patients to differentiate how their skin felt and may 
have influenced the patient component of the RISRAS scores. 
 
 The initial skin assessment was subject to recall and reporter bias. Patients were questioned 
about their past medical history and lifestyle. It is possible that some will under-report certain 
lifestyle choices, such as smoking, as there is a stigma associated with this. The research 
assistant used the patients’ oncology notes to verify information wherever possible. In the 
oncology notes two patients who had previously told the research assistant they were non-
smokers had in fact only just decided to quit so had actually been smoking until that time.  
 
 Potential lack of compliance. Adherence to the trial protocol was difficult to assess. Patients 
were instructed to apply Sorbolene Cream to the control area twice daily throughout their 
treatment and follow-up time. Measuring compliance was not possible in this context, 
although all patients insisted they were following the trial instructions. For many patients, the 
Mepitel Film fell off during the night for the first few weeks of treatment, especially those on 
the prophylactic trial. It would have been possible therefore for the patients to accidentally 
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assistant. It was easy to establish whether or not Mepitel Film was removed or had fallen off 
as patients cannot reapply it once it has come off. 
 
 The cohort was very small (12 patients). A potential problem with small cohorts is that one 
patient can have a significant effect on the average outcomes. For example patient CRT07 had 
a much higher RISRAS score than the other patients on the trial, (combined score for the Film 
was 5.77, combined score for the Sorbolene was 8.15) which would have increased the 
average severity score as well as the SD and SEM. However, even in this 12 patient cohort the 
difference in skin reaction severity and peak reaction scores between Mepitel Film and cream 
were still statistical significant. 
 
 Gender bias: This study also recruited far more males (9) than females (3) and this is a 
reflection of the gender distribution for H&N cancer patients in NZ (84). Recruiting more 
women was beyond the resources of this trial. 
 
 Location bias. Only patients from Canterbury were recruited because they could attend four 
weekly follow-up appointments. Thirteen patients who were screened were excluded based 
on this. Being able to remotely see patients via video conference would have meant these 
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5.  Conclusions and future directions 
 
Radiation-induced skin reactions are a common occurrence during radiation therapy treatment for 
head and neck cancer patients. There is a lack of evidence supporting the use of any one topical agent 
for the reduction of skin reactions, particularly for this cohort of patients.  
 
This honours thesis reports and analyses the results of the first 12 patients of a feasibility study that 
will include 30 patients from two New Zealand centres and one Chinese centre. The aim of this 
randomised controlled feasibility study was to investigate whether Mepitel Film dressings were 
superior to Sorbolene cream in reducing or managing radiation-induced skin reactions in patients with 
head and neck cancer.   
 
Even within the small sub-cohort in this thesis it appears that this cohort does not respond to Mepitel 
Film in the same way breast cancer patients do. The significantly higher dose to the skin of head and 
neck patients may mean that protection against friction will never completely prevent MD. Issues with 
beard growth pushing the film away from the skin surface and tougher skin in the neck area have all 
been identified as barriers to using Mepitel Film for these patients, particularly in a prophylactic 
setting.  
 
However, the Mepitel Film did offer some protection: even in this small cohort the differences in 
RISRAS measures between intervention and control skin areas did reach statistical significance, even 
if the protection is of a small size (30% rather than 90% in breast cancer patients).  
 
Using VMAT to deliver radiation therapy may decrease the skin dose to the extent that Mepitel Film 
may achieve improved results. This will be further explored in the analysis of the larger feasibility 
study. 
 
Although radiation-induced skin reactions do contribute to reductions in quality of life, patients with 
cancer of the head and neck experience several other side effects that can exacerbate their levels of 
stress. There is no evidence however in this small cohort of patients that stress levels have an effect 
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Preliminary results from the Chinese cohort of nasopharyngeal cancer patients (n=11), suggest that 
prophylactic use of Mepitel Film has a stronger protective effect than in the NZ cohort. The Chinese 
cohort of mainly men receive bilateral 50Gy/25# to cover the neck nodes with a skin dose between 
35 and 45 Gy. In addition, Chinese men do not have full or heavy beards and they did not experience 
problems with the Mepitel Film coming off in the first weeks of treatment. The few women in the NZ 
trial seemed to derive more benefit from Mepitel Film, so further studies in female head and neck 
patients would be useful as well, even though recruitment will be slow as women make up such a 
small fraction of the head and neck cohort. 
 
It appears that Mepitel Film tends to protects sub-lethally damaged skin from friction damage but for 
it to be effective it needs to adhere closely to the skin and the dose cannot be over 40Gy. These 
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Appendix A: Recent trials investigating the prevention of radiation-induced skin reactions 
Reference Cohort  randomised blinded Skin dose 
measured 
Measure  Follow up Intervention  control result P values 
Herst 2014 34 breast 
36 chest 
wall  
Intra-patient no yes RISRAS RTOG 
3x a week 
4 weeks Mepitel Film Aqueous 
Cream 
90% decrease in RISRAS 








Inter-patient yes no CTCAE, STAT, 
Skindex 
6 weeks Emu oil Cottonseed 
oil 
Patients with emu oil seemed to have slightly 
worse CTCAE scores, SKindex scores tended to 







271 prostate  none no no ‘Acute radiation 
dermatitis’ but 
did not mention 
how it was 
scored 
4 weeks Airwall tape multiple Difference in development of grade 2 and 3 
reactions between intervention and control 
group (21 and 0 vs 57 and 4) 
P<0.001. 
Cui 2015 94 
nasopharynx 
Inter-patient single no VAS and RTOG 2 weeks Olive oil Water Grades I and II occurred in 93.6% of 
intervention group and 72.3% of control group. 
Grade III occurred in 6.4% and 27.7% 
P<0.01 
Palatty 2014 50 head and 
neck 
Inter-patient single no RTOG 2 weeks Turmeric and 
sandalwood 
oil cream 
Baby oil Reduction in all grades of dermatitis at all time 
points. Grade III was lower in the intervention 
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Chan 2014 174 total 
89 breast 
20 lung 
65 head and 
neck 
Inter-patient double no CTCAE 4 weeks Allantoin Aqueous 
cream 
Aqueous cream seemed to reduce skin 
reactions compared to intervention. Skin 








HAD and DLQI 
2 weeks Mometasone 
furoate 
 
Diprobase Mean RTOG scores less for intervention, Max 
and mean erythema scores were also less 
P=0.046, 
0.018, 0.12 




Base cream Mean value of skinn damage using photo shop 
was lower in the Boswellia group, however 




Manas 2015 19 head and 
neck 
79 breast 
Inter-patient no no CTC 2 weeks R1 and 2 
cream (water 





R1 and 2 reduced the grade of dermatitis. At 2 
week f/u, 66.7% had no dermatitis compared 
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Appendix B: Recent trials investigating the management of acute radiation dermatitis. 
Reference Cohort  randomised blinded Skin dose 
measured 
Measure  Follow up Intervention  control result P values 
Paterson 
2012 






Mepilex Lite Aqueous 
Cream 
Meplix Lite dressings did not reduce the 
incidence of moist desquamation but did 
reduce the overall severity of skin reactions by 
41% 
P<0.001 
Zhong 2013 88 
nasopharynx 




Mepilex Lite saline Dermatitis healed faster Mepilex group than 
the control group (median 16 vs 23 days) 
P=0.009 
Bazire 2015 278 breast Inter-patient no no colourimetry Last 
assessment 





This study did not demonstrate any significant 
difference between Hydrosorb and placebo for 
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PARTICIPANT INFORMATION SHEET 
 
Study title: Skin Reactions during Radiation Therapy  
 
Principal investigator: Name:  Dr Patries Herst 
Department: Radiation 
Therapy (UOW) 
Position: Senior lecturer 




You are invited to take part in a clinical trial. A clinical trial is a type of research study. Please read the 
information in this form carefully; it tells you why we want to do the trial and what it means for you to take 
part. The research radiation therapist will talk to you about the trial and will be able to answer any questions 
you may have about it or your involvement. Please feel free to discuss your participation in this trial with 
family, whanau and friends and take your time to decide whether you would like to take part. All 
participation in this study is entirely voluntary (your choice) and even if you decide to take part now and 
change your mind later, you are free to withdraw at any time. Whether you decide to participate in the study 
or not, your current or future healthcare will not be affected in any way. 
 
If you decide to take part in the study, you will be asked to sign the pages at the end of this form to show 
that you have agreed to take part. You will be given a copy of the participant information sheet and consent 
form to take home with you. 
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Thank you for taking the time to read this information sheet. 
 
 
1. Why are we doing this study? 
This study compares the effect of Mepitel Film with that of a conventional moisturising cream on skin side 
effects in patients receiving radiation therapy for head and neck cancer. 
 
You have been invited to take part in this study because you have been diagnosed with head and neck 
cancer and are about to undergo radiation treatment at Christchurch Hospital. Radiation therapy is given 
with the aim of getting rid of all cancer cells in the area. Irradiation often causes skin reactions (side effects), 
which can vary from a slight reddening skin to severe redness and itching (which is comparable to sunburned 
skin). In some cases the skin may peel away in places, leaving the underlying tissues exposed. There is no 
standard way to prevent the skin reacting like this to radiation therapy.  
 
We have already done three skin trials in New Zealand that compared soft silicone dressings with 
moisturising cream in breast cancer patients. We found that the dressings reduced the severity of the skin 
reactions. Our latest study showed that when a very thin transparent (see-through) silicone film is applied to 
breast skin on the first day of treatment, severe skin reactions can be avoided. However, it is not always 
practical to apply the film to the entire area of skin that will be irradiated. In this study we want to wait until 
the skin turns a very faint pink before applying the dressing. This silicone film has not been trialled in head 
and neck cancer patients until now. 
 
 
2. Who will be asked to participate in this study? 
All patients who come to the department to receive radiation therapy for squamous cell carcinoma of the 
head and neck region will be approached with information about the study by the research radiation 
therapist. However patients who have had previous radiation therapy to the head and neck area, who have 
metastatic disease (spread beyond the neck region), who have facial hair in the treatment region, who have 
a K score of <70, or who are not able to attend the follow up visits after completion of treatment will NOT be 





3. What does my participation in the study involve? 
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 Once you have been accepted into the trial and you have signed the consent form, the research 
radiation therapist will do an initial assessment of your skin to tell us what your skin looks like before you 
start radiation treatment. You will also be asked information general information about your health that 
may affect your likelihood of getting severe skin reactions during your radiation treatment.  
 
 Baseline photos will be taken of the skin in the H&N area. Semi-permanent marker pens will be used to 
indicate which skin area will be covered in Film and which will be treated with sorbolene cream and 
photographs will be taken of these areas. Additional photographs may be taken in case you have a 
severe skin reaction. Parts of these photos may be used, with your permission, for reporting or 
publication purposes. You will not be able to be identified in any of these photographs. 
 
 During the first few weeks of your treatment, we will measure how much radiation your skin receives 
each day. We will do this by placing small flat squares directly on your skin (see Figure 1 below). These 
small squares contain special equipment that measures the exact amount of radiation received by your 




Figure 1: A small white square on this finger nail is called a dosimeter 
and squares like this will be placed on your skin to measure how much 





 You will be seen three times a week by the research radiation therapist, who will check your skin to see if 
there is any reaction to the radiation treatment and who will record these findings on an assessment 
form. The assessment form consists of a researcher part which will be filled in by the research radiation 
therapist and a patient part which you will be asked to fill in. This part will ask you to compare how 
comfortable your skin feels underneath the film and underneath the cream. 
 
 Based on your initial planning scan, an area of your skin that will get the highest dose will be selected as 
the trial area. This area of your skin will be divided into two halves. One half will be covered in film by 
the research radiation therapist, whilst we will ask you to put moisturising cream twice a day on the 
other half.  
 
 After you finish your course of radiation therapy we ask you to come back to the department once a 
week until your final check-up four weeks later (which is part of your normal hospital care) so we can 
keep checking your skin and recording the severity of any skin reactions you may develop once you finish 
your radiation treatment. 
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 Once a week you will also be asked to fill out a brief questionnaire (the cancer distress thermometer) 
about how stressed you feel before, during and after your radiation therapy treatment.  
 
 After you have completed this trial we will ask you to fill out a brief questionnaire that will ask you about 
your experiences of being on the trial and using the Mepitel Film. 
 
 
4.  Are there any risks to me if I participate in this study? 
 Our experience with the film has shown us that it is very comfortable to wear and makes the skin 
reactions less severe.  
 
 In the unlikely event of an adverse reaction to the film we will ask you to stop using it and treat the 
affected skin with a moisturising cream instead. 
 
 In the unlikely event of a physical injury as a result of your participation in this study, you may be covered 
by ACC under the Injury Prevention, Rehabilitation and Compensation Act. ACC cover is not automatic and 
your case will need to be assessed by ACC according to the provisions of the 2002 Injury Prevention 
Rehabilitation and Compensation Act. If your claim is accepted by ACC, you still might not get any 
compensation. This depends on a number of factors such as whether you are an earner or non-earner. 
ACC usually provides only partial reimbursement of costs and expenses and there may be no lump sum 
compensation payable. There is no cover for mental injury unless it is a result of physical injury. If you have 
ACC cover, generally this will affect your right to sue the investigators. If you have any questions about 
ACC, contact your nearest ACC office or the investigator. 
 
 
5. Are there any costs involved if I participate in this study? 
There are no costs associated with this trial. You will be reimbursed for any follow up sessions that are not 
part of standard care (up to $25 per visit). 
 
 
6. What will you do with the information? 
Information that may identify you, such as your name, address and date of birth, will be kept together with your 
medical records, skin reactions and exit questionnaire in your patient file in the oncology department.  
 
The Principal Investigator, Dr Patries Herst, will collate and analyse all the information. She will receive your 
information in a form that is no longer linked to your name, address or date of birth. You will be given a special trial 
number to which all the trial information is linked.    
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This de-identified information will be stored in in locked metal filing cabinet in the office of the Principal Investigator, 
Dr Patries Herst, at the University of Otago, Wellington for a period of 10 years. Only the research radiation therapist 
will be able to link the de-identified information to you personally.  
 
When the study is completed the principal investigator, Dr Patries Herst will collate and analyse the 
information from all the participants of the study. This will tell us whether the film is better than the cream 
in managing skin reactions. If this is the case, we aim to conduct a larger trial, and we would like to 
incorporate the data from this trial into a larger future study. 
 
We anticipate that this will lead to a standardized treatment for radiation-induced skin reactions for head 




 We will report on the results of this study in scientific reports and publications.  
 If you so wish, you can be informed of the results of the study by a letter written in lay terms from the  
Principal Investigator, Dr Patries Herst 
 
NO material will be published which can identify you personally. 
You may be asked if we can use photos of parts of your skin to illustrate our findings. You will in no way be 
able to be identified by these photos.  
 
 
7. Do I have to participate in this study? 




8. Can I withdraw from the study if I change my mind? 
If you decide to take part in the study now and change your mind later, you are free to withdraw from the 
study at any time. Whether you decide to participate in the study or not will not affect your current or future 
healthcare in any way. 
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If you wish to withdraw, please advise the research radiation therapist. We will keep the information we 
have collected about you for our analysis. However, if you request it, all information and data that have been 
collected about you will be completely deleted from the database.  
 
9. What if I have more questions or concerns about this study? 
If you have any questions or concerns about your rights as a participant in this research study you can 
contact an independent health and disability advocate. This is a free service provided under the Health and 
Disability Commissioner Act. Local (03) 479 0265; Telephone: (NZ wide) 0800 555 050; Free Fax (NZ wide):  
0800 2787 7678 (0800 2 SUPPORT); Email (NZ wide): advocacy@hdc.org.nz. If there is a specific Māori 
issue/concern please contact Linda Grennell at 0800 37 77 66I. 
 
 
If you have any questions or concerns about your skin reactions or any other aspects of this study, at any 
time, please call the Research Radiation Therapist: Hayley Wooding phone: 3640020 ext 88487 
 
 
This study has been approved by the University of Otago Human Ethics Committee (trial number H14/111). If 
you have any concerns about the ethical conduct of the research you may contact the Committee through 
the Human Ethics Committee Administrator (ph 03 479 8256). Any issues you raise will be treated in 
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Skin Reactions during Radiation Therapy  
 
 
Principle investigator: Dr Patries Herst  (patries.herst@otago.ac.nz;  
      mobile: 027-3483945) 
 
 
Name of Participant ………………………………………………………………... 
 
1. I have read and I understand the information sheet dated September 2015 for volunteers taking part in 
the study designed to investigate whether Mepitel Film decreases the severity of skin reactions caused 
by radiation therapy. 
2. I have had the opportunity and time to discuss this study with family, whanau and friends.  I am satisfied 
with the answers I have been given. 
3. I understand that taking part in this study is completely voluntary (my choice), and that I may withdraw 
from the study at any time, without giving a reason and this will in no way affect my future health care. 
4. I understand that my participation in this study is confidential and that no material that could identify 
me will be used in any reports on this study. 
5. I understand that the film will be removed if it I have a reaction to it. 
6. I know who to contact if I have any questions about the study. 
7. As a participant I agree to: 
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 Regular skin reaction assessments by the research radiation therapist, which will be carried out three 
times a week during treatment as well as once a week after the completion of treatment until the 
final check-up four weeks after treatment. The skin assessment form has a patient part to be filled in 
by myself and a researcher part to be filled in by the research radiation therapist. 
 
 Use of photographs that may be taken of parts of my skin for publication purposes as long as I 
cannot be identified from these photos.  
 
 Filling in the distress thermometer questionnaire once a week during the study. 
 
 Filling in an exit questionnaire at the end of the study that will allow me to describe my experiences 




I consider my ethnicity to be: 
 
O New Zealand European 
O Mäori  
O Samoan 





O Other (such as Dutch, Japanese, Tokelauan). Please state. 
I,  ………………………………………………. (full name) hereby consent to  






Full names of researchers: Hayley Wooding, Dr Iain Ward 
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Contact phone number for 
researchers: 
3640020 ext. 88487 
  
Project explained by:  
  






This study has been approved by the University of Otago Human Ethics Committee. If you have any concerns 
about the ethical conduct of the research you may contact the Committee through the Human Ethics 
Committee Administrator (ph 03 479 8256). Any issues you raise will be treated in confidence and 
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Appendix E: Randomisation sheet 
Randomisation coversheet 
Effect of Mepitel Film on skin reaction severity in Head and Neck cancer patients 
 
Date:  
To: Patries Herst 
Email: patries.herst@otago.ac.nz 







Patient initials:   
Patient DoB: 
Gender: 
Chemo/RT  RT alone  
Mepitel Film:  Superior/Lateral:  
   Inferior/Medial:  
Patient randomisation number:  
Randomisation date:  
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Appendix F: Skin care guidelines 
 
1.1   Acute Radiation Therapy Skin Reactions: Guidelines for 
Management 
 
1.2   Purpose/Objective 
 
Management of acute radiation skin reactions is systematic, evidence-based and 
multi- disciplinary in approach 
 
1.3   Personnel Authorised to Perform Procedure 
 
Radiation Therapists - for patients who have been assessed to have reactions in the categories 
of erythema and dry desquamation 
Registered Nurses – assess, plan and deliver care for patients with reactions in the categories 
of erythema, dry desquamation, moist desquamation or necrosis 
Enrolled Nurses may deliver care planned and supervised by Registered Nurses or Medical 
Practitioners 





1.4   Definitions 
Acute Radiation Therapy Skin Reaction Policy 
On Treatment Review Protocol 
Patient Education Protocol 
 
The four main categories of acute radiation-induced skin reactions are as follows (Naylor & 














Reddened skin, which may be 
oedematous and feel hot and irritable 
 
Dry, flaky or peeling skin that may be 
itchy 
 
Peeling skin with exposure of the dermis 
and exudate production, often painful 
and may become infected 
 
Death of tissue, skin may darken and 
turn black 
1.5   Assessment Tool 
 
 
The CTCAE v 4.0 is used to assess symptom toxicity. 
 
1.6   Guideline 
 
This framework is based on current best-practice evidence. Outcomes to be achieved are: 
 To ensure and enable best supportive care of patients undergoing radiation 
treatment, acknowledging information and education needs of patients and 
carers 
     Identify risk factors for acute radiation skin reactions occurring 
     Promote principles of optimum wound healing, minimising the risk of infection 
4074137 
15 | P a g e  
 
     To ensure continuity across acute/community settings 
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 To be undertaken prior to, during and post radiation treatment on an ongoing basis by health-care 
professionals who have knowledge and understanding of the principles and practice of radiation 
skin care management. Toxicity is graded weekly by the Radiation Oncologist using the CTCAE v4.0. 
 
 
     This should include actual and potential risk factors including: 
     fractionation 
     concomitant techniques 
     radiation energy and type 
     treatment technique 
     volume and dose of radiation 
     nutritional status 
     use of radio-sensitising drugs 
     area receiving radiation 
     current skin condition 
     areas of skin already exposed to trauma: surgery, skin disorders 
 patient factors – immobility, work environment, limited self care ability, age, medical 
conditions. 
     identification of information needs of patients and/or carers 
     identification and documentation of changes in skin condition 
     any changes in treatment 2 Implementation 
The process of implementation includes: 
     clear, consistent written and verbal information available for patients and care-givers 
 care planned within a multi-disciplinary context. This includes as appropriate: dietitian, 
occupational therapist, speech-language therapist, physiotherapist, wound care nurse 
specialist 
 ongoing needs of patients and care-givers during treatment and rehabilitation 
are acknowledged 
3 General Skin Care Advice 
The following information must be available in written form for patients and carers: 
 skin in the radiation treatment area may be washed with warm water, using non-
perfumed non-alkaline or pH neutral soaps or shampoos for washing e.g. Dove ® . 
     deodorant may be used 
     pat the area dry, avoid rubbing 
     wear loose clothes made from natural fibres 
 shaving should be avoided within the radiation therapy field. If absolutely necessary use of 
an electric razor is recommended 
     skin should be protected from extremes of temperature 
 avoid sunscreen in the treatment area. Sunscreen (factor 30+) should be used on all 
other exposed skin and remain continuous throughout life. 
 FattyE Cream may be used for comfort if erythema or dry desquamation present. Not to 
be used on broken skin. 
     Aloe Vera has no proven benefit in radiation skin reactions but may be used if patient wishes 
     saline baths or soaks can be used as required (remove soaks before they dry out) 
     take care to preserve skin markings 
     avoid alcohol based products and the use of powders 
     using tape to secure dressings within the treatment field should be avoided 
     if reaction occurs patients should seek advice regarding swimming in chlorinated water 
     Patient Information Sheets on skincare are available on ‘G’ drive under Common/Patient 
Information/Radiation/RT NP education. 
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The development of a pink-red area 2-3 weeks into radiation treatment may occur. This is caused by the 
release of histamine-like substances from damaged dermal cells, leading to dermal oedema, 
erythrocyte extravasation and dilation of capillaries. Leading to the various shades of skin redness. 
     Refer to General Skin Care Advice for management 
 
Transient Erythema 
The development of a pink-red area which occurs with the first or second dose of radiation being given. This 
reduces within a matter of hours to days within commencing treatment. 
     Reassure patient this is an initial temporary reaction 
 
Dry desquamation 
The basal cells injured at the beginning of treatment continue their normal upward progression through the 
epithelium, reach the corneocytic stage, become cornified and shed. If the basal layer has been 
repaired before desquamation, the skin surface remains dry. 
 
Patients may complain of discomfort, burning or itching. They may also experience superficial flaking of 
the epidermis. 
Principles of management include: 
 regular assessment and documentation by health-care professional, daily for inpatients and 
on treatment days for patients receiving treatment 
     continue with general skin care management 
     moisturise the area 2-3 times a day with FattyE cream or similar, avoiding macerated skin. 
 water soaked gauze applied for 10-15 minutes as required may be soothing for heat 
and itchiness 
    decrease friction if this is an issue by applying barrier protection which can be removed easily 
for treatment e.g. Mepilex lite 
    hydrocortisone 1% may be considered by medical staff for itchy skin if unrelieved by other 
measures. Apply sparingly BD-TDS. Not on broken or infected areas.  May delay healing time 
and affect skin integrity if used long term. 
    Grade 1 erythema may be treated with a thin application of Cavilon™ 
5  
Moist desquamation 
Loss of the epidermis resulting in exposure of the dermis with associated exudate production, pain and risk 
of infection. 
 
Principles of management include: 
 regular assessment and documentation by health-care professional, daily for inpatients and  
on treatment days for patients receiving treatment 
     a moist wound healing environment 
     assessment of analgesic requirements for dressing 
     cleansing as required using tepid normal saline, saline soaks used as required may be soothing 
     During treatment: 
Light to moderate exudating reaction sites: 
     Cover with a low adherent dressing (e.g. Jelonet/ Adaptic/ Mepilex transfer™) 
and secondary dressing such as gamgee secured with tubifast 
     Remove before treatment and reapply after daily 
treatment. 
 
 Consider use of Cuticerin/Jelonet or similar and combine or similar secured with tubifast® as a 
primary dressing for moderate-heavy exudating reaction sites. 
 
     Application of dressings intended to stay in place during treatment need to be discussed with the 

















     At completion of treatment – 
Continue with dressing regimen  working in reverse as skin heals with regular review by a health care 
professional at follow-up or in the community 
Infected Wounds 
Infection is characterised by the presence of redness, pain, swelling, heat, odour and 
exudate. Principles of Management include: 
    assessment of analgesia requirements for dressing change 
    identifying type of wound infection, obtain swab and send for micro/culture + sensitivity 
    cleansing as required with warmed normal saline 
    assessing level of exudate and choosing appropriate wound product to contain exudate 
     assessing odour level, consider use of activated charcoal dressings. Essential oils e.g. tea tree or 
eucalyptus, may be applied to outside of  dressing if acceptable to patient 
 
Consider use of topical or systemic antibacterial agents dependent on result of swab. These may 
include Metronidazole gel, silver based agents or iodine based agents. Application of these products is 
done in consultation with Wound Care Clinical Nurse Specialist and Radiation Oncology Team. 
 
Wound would be cleaned prior to radiation treatment with use of these products and reapplied 
post treatment 
 
 Silver based products are not to be used during treatment period but may be considered 
on treatment completion 
 
Ongoing assessment by a Registered Nurse and in consultation with a Medical Practitioner is required 




Malignant fungating wounds arise when cancer cells infiltrate and proliferate within the skin resulting in 
the development of nodular and/or ulcerating wounds (Naylor, 2005) 
 
Symptoms to consider with fungating wounds include malodour, exudate, pain, bleeding and 
psychosocial aspects for the patient 
 
 
Principles of Management include: 
 
 assessing psycho-social impact on patient and family. Refer to appropriate multidisciplinary team 
member as required 
 identifying and treating infection which may contribute to malodour – obtain swab 
for micro/culture + sensitivity, topical or systemic treatment as needed 
     assessing pain levels and analgesia requirements for dressings 
     assessing and treating odour: 
o treat infection if odour causing 
o consider use of dressings with activated charcoal to absorb 
odour or use of essential oils 
 
Exudate 
o Low - consider a thin hydro gel remove prior to treatment 
 
o Moderate – consider Allevyn™, or Mepilex Lite™ 
 
o Heavy - consider Combine, Mesorb/Mepilex Transfer/Mepitel™ 
 
o If extremely heavy consider wound drainage bags or disposable pads 
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     Bleeding – may be very little or large 
o consider haemostatic dressings e.g. alginates – Kaltostat, Seasorb or similar, for small 
amounts. 
o large amounts can be life threatening, apply pressure and obtain help. 
 
 If persistent bleeding, consider complete blood count to monitor parameters as may affect 
radiation effectiveness 
 
     Necrosis requires input from the Wound Care Nurse Specialist, Plastics team or General Surgery. 




While on treatment out-patients will be reviewed every treatment day by the radiation therapist and 
nursing staff 
 
In-patients will be reviewed by the ward nurse in consultation with oncology inpatient CNS. Radiation 
oncology nurses may be contacted on 89504 for advice if needed. 
 
On completion of treatment a community referral should be made, if required, with specific care instructions 
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Reproduced with permission from The NCCN (v.1.2005) Distress Management Guideline, The Complete 
Library of NCCN Clinical Practice Guidelines in Oncology [CD-ROM] Jenkintown, Pennsylvania: 
© National Comprehensive Cancer Network, June 2006. T view the most recent and complete version of  
the guideline, go online to www.nccn.org                                  11.05.06 
Cancer Related Distress Screen 
 
Please indicate if any of the following has been a problem for you in 
the past week including today. Be sure to check Yes or No for each. 
       
       
Yes No Spiritual (Wairua)  Yes No Physical (Tinana)  
  Concerns    Problems 
      Appearance 
  Practical Problems    Bathing/Dressing 
  Child care    Breathing 
  Housing    Changes in urination 
  Financial    Constipation 
  Transportation    Diarrhoea 
  Work / school    Eating 
  Cultural obligations    Fatigue 
  Hospital Processes   Feeling Swollen 
      Fevers 
  Family (Whanau)     Getting around 
  Problems    Indigestion 
  Dealing with children    Memory/concentration 
  Dealing with partner   Mouth sores 
  Other family    Nausea 
  members   Nose dry / congested 
  Family/Whanau     Pain 
  dealing with the    Sexual 
  situation    Skin dry / itchy 
      Sleep 
  Emotional    Tingling in hands /feet 
  (Hinengaro) Problems    
  Depression  Other Problems 
  Fears     
  Anxiety  ____________________________ 
  Sadness     
  Worry  ____________________________ 
  Loss of interest in      
  usual activities  ____________________________ 
 
 
Please circle the 
number (0-10) that 
best describes how 
much distress 
(mamae) you have 
been experiencing in 









Please circle the 
number (0-10) that 
best describes how 
much impact this 
distress (mamae) has 
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Appendix H: Exit Questionnaire 
Mepitel Film Exit Questionnaire 
 
1.  Was taking part in this trial a positive experience for you?                
                                                                                                                         Yes/No 










2.  Do you think that the dressings were better than the cream in managing your 
           skin reactions?                                                   
                                                                                                                         Yes/No 










3. What were the advantages of the Mepitel Film dressings for you? 
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4.  What were the disadvantages of the Mepitel Film dressings for you? 












5.  Based on your experience with this trial, would you take part in other clinical            
trials when appropriate?                                        
                                                                                                                           Yes/No 
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6. Would you like the results of this trial sent to you?                  Yes/No 
 
 
Thank you for taking part in this trial. This valuable research would not be possible 
without your help.  
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Appendix I: Fitzpatrick Skin type assessment 
Fitzpatrick skin-type chart      Patient no:  Randomisation:      
      
Genetic disposition     
  0 1 2 3 4 
Eye colour Light blue Blue Blue Dark brown Brownish Black 
  Light grey Grey       
  Light green Green       
Hair colour Sandy red Blonde Lt brown Dark brown Black 
      Dark blonde     
Skin colour Reddish Very pale Pale 
Light 
brown Dark brown 
      Beige tint     
Freckles Many Several Few Incidental None 
            
      
Total score =       
      
Reaction to sun exposure     
  0 1 2 3 4 








Rarely burn Never burn 









Never Seldom Sometimes Often Always 
Reaction of 
face to sun 
V. sensitive Sensitive Normal 
Very 
resistant 
Never had a problem 
      
Total score =       
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Tanning habits      
  0 1 2 3 4 










<2 weeks ago 
Last exposed 
area to be 
treated? 
Never Hardly ever Sometimes Often Always 
      
Total score =       
      
Fitzpatrick Skin type score     
0-7 I   Highly sensitive - always burns - never tans  
8-16 II 
  Very sun sensitive - burns easily - tans 
minimally  
17-25 III   Sun sensitive skin - sometimes burns - slowly tans light brown 
26-30 IV 
  Minimally sun sensitive - burns minimally - tans mid 
brown  
>30 V-VI   Sun insensitive skin - rarely/never burns -  deeply pigmented 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
